id	sid	tid	token	lemma	pos
bjp-38807	1	1	bangladesh	bangladesh	PROPN
bjp-38807	1	2	journal	journal	PROPN
bjp-38807	1	3	of	of	ADP
bjp-38807	1	4	pharmacology	pharmacology	NOUN
bjp-38807	1	5	clinical	clinical	ADJ
bjp-38807	1	6	trial	trial	NOUN
bjp-38807	1	7	efficacy	efficacy	NOUN
bjp-38807	1	8	and	and	CCONJ
bjp-38807	1	9	safety	safety	NOUN
bjp-38807	1	10	of	of	ADP
bjp-38807	1	11	regorafenib	regorafenib	NOUN
bjp-38807	1	12	versus	versus	ADP
bjp-38807	1	13	dinutuximab	dinutuximab	NOUN
bjp-38807	1	14	with	with	ADP
bjp-38807	1	15	chemotherapy	chemotherapy	NOUN
bjp-38807	1	16	in	in	ADP
bjp-38807	1	17	chinese	chinese	ADJ
bjp-38807	1	18	children	child	NOUN
bjp-38807	1	19	with	with	ADP
bjp-38807	1	20	neuroblastoma	neuroblastoma	ADJ
bjp-38807	1	21	bjp	bjp	NOUN
bjp-38807	1	22	introduction	introduction	NOUN
bjp-38807	1	23	neuroblastoma	neuroblastoma	NOUN
bjp-38807	1	24	in	in	ADP
bjp-38807	1	25	children	child	NOUN
bjp-38807	1	26	is	be	AUX
bjp-38807	1	27	one	one	NUM
bjp-38807	1	28	of	of	ADP
bjp-38807	1	29	most	most	ADV
bjp-38807	1	30	commonly	commonly	ADV
bjp-38807	1	31	diagnosed	diagnose	VERB
bjp-38807	1	32	cancer	cancer	NOUN
bjp-38807	1	33	and	and	CCONJ
bjp-38807	1	34	the	the	DET
bjp-38807	1	35	leading	lead	VERB
bjp-38807	1	36	cause	cause	NOUN
bjp-38807	1	37	of	of	ADP
bjp-38807	1	38	cancer	cancer	NOUN
bjp-38807	1	39	mortality	mortality	NOUN
bjp-38807	1	40	in	in	ADP
bjp-38807	1	41	the	the	DET
bjp-38807	1	42	world	world	NOUN
bjp-38807	1	43	,	,	PUNCT
bjp-38807	1	44	accounting	account	VERB
bjp-38807	1	45	for	for	ADP
bjp-38807	1	46	more	more	ADJ
bjp-38807	1	47	than	than	ADP
bjp-38807	1	48	15	15	NUM
bjp-38807	1	49	%	%	NOUN
bjp-38807	1	50	.	.	PUNCT
bjp-38807	2	1	the	the	DET
bjp-38807	2	2	incidence	incidence	NOUN
bjp-38807	2	3	and	and	CCONJ
bjp-38807	2	4	mortality	mortality	NOUN
bjp-38807	2	5	of	of	ADP
bjp-38807	2	6	childhood	childhood	NOUN
bjp-38807	2	7	neuroblastoma	neuroblastoma	NOUN
bjp-38807	2	8	have	have	AUX
bjp-38807	2	9	increased	increase	VERB
bjp-38807	2	10	steadily	steadily	ADV
bjp-38807	2	11	(	(	PUNCT
bjp-38807	2	12	kushner	kushner	PROPN
bjp-38807	2	13	,	,	PUNCT
bjp-38807	2	14	2004	2004	NUM
bjp-38807	2	15	;	;	PUNCT
bjp-38807	2	16	boubaker	boubaker	NOUN
bjp-38807	2	17	and	and	CCONJ
bjp-38807	2	18	bischof	bischof	NOUN
bjp-38807	2	19	,	,	PUNCT
bjp-38807	2	20	2003	2003	NUM
bjp-38807	2	21	;	;	PUNCT
bjp-38807	2	22	hiorns	hiorn	NOUN
bjp-38807	2	23	and	and	CCONJ
bjp-38807	2	24	owens	owen	NOUN
bjp-38807	2	25	,	,	PUNCT
bjp-38807	2	26	2001	2001	NUM
bjp-38807	2	27	;	;	PUNCT
bjp-38807	2	28	schwab	schwab	PROPN
bjp-38807	2	29	et	et	PROPN
bjp-38807	2	30	al	al	PROPN
bjp-38807	2	31	.	.	PROPN
bjp-38807	2	32	,	,	PUNCT
bjp-38807	2	33	2003	2003	NUM
bjp-38807	2	34	)	)	PUNCT
bjp-38807	2	35	.	.	PUNCT
bjp-38807	3	1	the	the	DET
bjp-38807	3	2	molecularly	molecularly	ADV
bjp-38807	3	3	targeted	target	VERB
bjp-38807	3	4	therapies	therapy	NOUN
bjp-38807	3	5	are	be	AUX
bjp-38807	3	6	being	be	AUX
bjp-38807	3	7	studied	study	VERB
bjp-38807	3	8	,	,	PUNCT
bjp-38807	3	9	and	and	CCONJ
bjp-38807	3	10	the	the	DET
bjp-38807	3	11	combination	combination	NOUN
bjp-38807	3	12	of	of	ADP
bjp-38807	3	13	targeted	target	VERB
bjp-38807	3	14	agents	agent	NOUN
bjp-38807	3	15	with	with	ADP
bjp-38807	3	16	chemotherapy	chemotherapy	NOUN
bjp-38807	3	17	may	may	AUX
bjp-38807	3	18	be	be	AUX
bjp-38807	3	19	advantageous	advantageous	ADJ
bjp-38807	3	20	.	.	PUNCT
bjp-38807	4	1	irinotecan	irinotecan	NOUN
bjp-38807	4	2	and	and	CCONJ
bjp-38807	4	3	temozolomide	temozolomide	NOUN
bjp-38807	4	4	can	can	AUX
bjp-38807	4	5	be	be	AUX
bjp-38807	4	6	safely	safely	ADV
bjp-38807	4	7	administered	administer	VERB
bjp-38807	4	8	to	to	ADP
bjp-38807	4	9	the	the	DET
bjp-38807	4	10	patient	patient	NOUN
bjp-38807	4	11	with	with	ADP
bjp-38807	4	12	relapsed	relapse	VERB
bjp-38807	4	13	or	or	CCONJ
bjp-38807	4	14	refractory	refractory	NOUN
bjp-38807	4	15	neuroblastoma	neuroblastoma	NOUN
bjp-38807	4	16	.	.	PUNCT
bjp-38807	5	1	the	the	DET
bjp-38807	5	2	monoclonal	monoclonal	NOUN
bjp-38807	5	3	antibody	antibody	NOUN
bjp-38807	5	4	as	as	ADP
bjp-38807	5	5	monotherapy	monotherapy	NOUN
bjp-38807	5	6	or	or	CCONJ
bjp-38807	5	7	combination	combination	NOUN
bjp-38807	5	8	with	with	ADP
bjp-38807	5	9	the	the	DET
bjp-38807	5	10	chemotherapy	chemotherapy	NOUN
bjp-38807	5	11	is	be	AUX
bjp-38807	5	12	the	the	DET
bjp-38807	5	13	standard	standard	ADJ
bjp-38807	5	14	therapy	therapy	NOUN
bjp-38807	5	15	for	for	ADP
bjp-38807	5	16	the	the	DET
bjp-38807	5	17	advanced	advanced	ADJ
bjp-38807	5	18	neuroblastoma	neuroblastoma	NOUN
bjp-38807	5	19	.	.	PUNCT
bjp-38807	6	1	the	the	DET
bjp-38807	6	2	chemotherapeutic	chemotherapeutic	ADJ
bjp-38807	6	3	agents	agent	NOUN
bjp-38807	6	4	commonly	commonly	ADV
bjp-38807	6	5	used	use	VERB
bjp-38807	6	6	in	in	ADP
bjp-38807	6	7	clinical	clinical	ADJ
bjp-38807	6	8	practice	practice	NOUN
bjp-38807	6	9	include	include	VERB
bjp-38807	6	10	irinotecan	irinotecan	NOUN
bjp-38807	6	11	or	or	CCONJ
bjp-38807	6	12	temozolomide	temozolomide	NOUN
bjp-38807	6	13	,	,	PUNCT
bjp-38807	6	14	and	and	CCONJ
bjp-38807	6	15	their	their	PRON
bjp-38807	6	16	combination	combination	NOUN
bjp-38807	6	17	regimens	regimen	NOUN
bjp-38807	6	18	.	.	PUNCT
bjp-38807	7	1	in	in	ADP
bjp-38807	7	2	recent	recent	ADJ
bjp-38807	7	3	years	year	NOUN
bjp-38807	7	4	,	,	PUNCT
bjp-38807	7	5	combination	combination	NOUN
bjp-38807	7	6	of	of	ADP
bjp-38807	7	7	temsirolimus	temsirolimus	NOUN
bjp-38807	7	8	and	and	CCONJ
bjp-38807	7	9	dinutuximab	dinutuximab	NOUN
bjp-38807	7	10	agents	agent	NOUN
bjp-38807	7	11	to	to	ADP
bjp-38807	7	12	chemotherapy	chemotherapy	NOUN
bjp-38807	7	13	regimens	regimen	NOUN
bjp-38807	7	14	,	,	PUNCT
bjp-38807	7	15	either	either	CCONJ
bjp-38807	7	16	in	in	ADP
bjp-38807	7	17	the	the	DET
bjp-38807	7	18	first	first	ADJ
bjp-38807	7	19	or	or	CCONJ
bjp-38807	7	20	second	second	ADJ
bjp-38807	7	21	line	line	NOUN
bjp-38807	7	22	for	for	ADP
bjp-38807	7	23	the	the	DET
bjp-38807	7	24	patient	patient	NOUN
bjp-38807	7	25	with	with	ADP
bjp-38807	7	26	neuroblastoma	neuroblastoma	NOUN
bjp-38807	7	27	,	,	PUNCT
bjp-38807	7	28	have	have	AUX
bjp-38807	7	29	significantly	significantly	ADV
bjp-38807	7	30	improved	improve	VERB
bjp-38807	7	31	overall	overall	ADJ
bjp-38807	7	32	survival	survival	NOUN
bjp-38807	7	33	,	,	PUNCT
bjp-38807	7	34	progression	progression	NOUN
bjp-38807	7	35	-	-	PUNCT
bjp-38807	7	36	free	free	ADJ
bjp-38807	7	37	survival	survival	NOUN
bjp-38807	7	38	,	,	PUNCT
bjp-38807	7	39	and	and	CCONJ
bjp-38807	7	40	response	response	NOUN
bjp-38807	7	41	rate	rate	NOUN
bjp-38807	7	42	(	(	PUNCT
bjp-38807	7	43	grothey	grothey	NOUN
bjp-38807	7	44	et	et	PROPN
bjp-38807	7	45	al	al	PROPN
bjp-38807	7	46	.	.	PROPN
bjp-38807	7	47	,	,	PUNCT
bjp-38807	7	48	2013	2013	NUM
bjp-38807	7	49	;	;	PUNCT
bjp-38807	7	50	cao	cao	PROPN
bjp-38807	7	51	et	et	PROPN
bjp-38807	7	52	al	al	PROPN
bjp-38807	7	53	.	.	PROPN
bjp-38807	7	54	,	,	PUNCT
bjp-38807	7	55	2016	2016	NUM
bjp-38807	7	56	;	;	PUNCT
bjp-38807	7	57	li	li	PROPN
bjp-38807	7	58	et	et	PROPN
bjp-38807	7	59	al	al	PROPN
bjp-38807	7	60	.	.	PROPN
bjp-38807	7	61	,	,	PUNCT
bjp-38807	7	62	2018	2018	NUM
bjp-38807	7	63	;	;	PUNCT
bjp-38807	7	64	xu	xu	PROPN
bjp-38807	7	65	et	et	PROPN
bjp-38807	7	66	al	al	PROPN
bjp-38807	7	67	.	.	PROPN
bjp-38807	7	68	,	,	PUNCT
bjp-38807	7	69	2017	2017	NUM
bjp-38807	7	70	)	)	PUNCT
bjp-38807	7	71	.	.	PUNCT
bjp-38807	8	1	however	however	ADV
bjp-38807	8	2	,	,	PUNCT
bjp-38807	8	3	the	the	DET
bjp-38807	8	4	majority	majority	NOUN
bjp-38807	8	5	of	of	ADP
bjp-38807	8	6	patients	patient	NOUN
bjp-38807	8	7	still	still	ADV
bjp-38807	8	8	developed	develop	VERB
bjp-38807	8	9	resistance	resistance	NOUN
bjp-38807	8	10	to	to	ADP
bjp-38807	8	11	the	the	DET
bjp-38807	8	12	standard	standard	ADJ
bjp-38807	8	13	treatment	treatment	NOUN
bjp-38807	8	14	(	(	PUNCT
bjp-38807	8	15	xu	xu	INTJ
bjp-38807	8	16	et	et	PROPN
bjp-38807	8	17	al	al	PROPN
bjp-38807	8	18	.	.	PROPN
bjp-38807	8	19	,	,	PUNCT
bjp-38807	8	20	2017	2017	NUM
bjp-38807	8	21	;	;	PUNCT
bjp-38807	8	22	motzer	motzer	NOUN
bjp-38807	8	23	et	et	PROPN
bjp-38807	8	24	al	al	PROPN
bjp-38807	8	25	.	.	PROPN
bjp-38807	8	26	,	,	PUNCT
bjp-38807	8	27	2007	2007	NUM
bjp-38807	8	28	)	)	PUNCT
bjp-38807	8	29	.	.	PUNCT
bjp-38807	9	1	regorafenib	regorafenib	PROPN
bjp-38807	9	2	is	be	AUX
bjp-38807	9	3	the	the	DET
bjp-38807	9	4	first	first	ADJ
bjp-38807	9	5	small	small	ADJ
bjp-38807	9	6	-	-	PUNCT
bjp-38807	9	7	molecule	molecule	NOUN
bjp-38807	9	8	multi	multi	ADJ
bjp-38807	9	9	-	-	ADJ
bjp-38807	9	10	kinase	kinase	ADJ
bjp-38807	9	11	inhibitor	inhibitor	NOUN
bjp-38807	9	12	of	of	ADP
bjp-38807	9	13	vegfr	vegfr	NOUN
bjp-38807	9	14	offers	offer	VERB
bjp-38807	9	15	survival	survival	NOUN
bjp-38807	9	16	benefits	benefit	NOUN
bjp-38807	9	17	in	in	ADP
bjp-38807	9	18	patient	patient	NOUN
bjp-38807	9	19	with	with	ADP
bjp-38807	9	20	solid	solid	ADJ
bjp-38807	9	21	cancer	cancer	NOUN
bjp-38807	9	22	who	who	PRON
bjp-38807	9	23	has	have	AUX
bjp-38807	9	24	grown	grow	VERB
bjp-38807	9	25	after	after	ADP
bjp-38807	9	26	first	first	ADJ
bjp-38807	9	27	/	/	SYM
bjp-38807	9	28	second	second	ADJ
bjp-38807	9	29	-	-	PUNCT
bjp-38807	9	30	line	line	NOUN
bjp-38807	9	31	of	of	ADP
bjp-38807	9	32	standard	standard	ADJ
bjp-38807	9	33	therapies	therapy	NOUN
bjp-38807	9	34	(	(	PUNCT
bjp-38807	9	35	kamba	kamba	NOUN
bjp-38807	9	36	and	and	CCONJ
bjp-38807	9	37	mcdonald	mcdonald	PROPN
bjp-38807	9	38	,	,	PUNCT
bjp-38807	9	39	2007	2007	NUM
bjp-38807	9	40	)	)	PUNCT
bjp-38807	9	41	.	.	PUNCT
bjp-38807	10	1	currently	currently	ADV
bjp-38807	10	2	,	,	PUNCT
bjp-38807	10	3	a	a	DET
bjp-38807	10	4	pharmacological	pharmacological	ADJ
bjp-38807	10	5	study	study	NOUN
bjp-38807	10	6	shows	show	VERB
bjp-38807	10	7	that	that	SCONJ
bjp-38807	10	8	regorafenib	regorafenib	NOUN
bjp-38807	10	9	is	be	AUX
bjp-38807	10	10	efficacious	efficacious	ADJ
bjp-38807	10	11	in	in	ADP
bjp-38807	10	12	suppressing	suppress	VERB
bjp-38807	10	13	the	the	DET
bjp-38807	10	14	tumor	tumor	NOUN
bjp-38807	10	15	abstract	abstract	NOUN
bjp-38807	10	16	the	the	DET
bjp-38807	10	17	objective	objective	NOUN
bjp-38807	10	18	of	of	ADP
bjp-38807	10	19	the	the	DET
bjp-38807	10	20	present	present	ADJ
bjp-38807	10	21	study	study	NOUN
bjp-38807	10	22	was	be	AUX
bjp-38807	10	23	to	to	PART
bjp-38807	10	24	evaluate	evaluate	VERB
bjp-38807	10	25	the	the	DET
bjp-38807	10	26	efficacy	efficacy	NOUN
bjp-38807	10	27	and	and	CCONJ
bjp-38807	10	28	safety	safety	NOUN
bjp-38807	10	29	of	of	ADP
bjp-38807	10	30	regorafenib	regorafenib	NOUN
bjp-38807	10	31	in	in	ADP
bjp-38807	10	32	comparison	comparison	NOUN
bjp-38807	10	33	with	with	ADP
bjp-38807	10	34	dinutuximab	dinutuximab	NOUN
bjp-38807	10	35	with	with	ADP
bjp-38807	10	36	chemotherapy	chemotherapy	NOUN
bjp-38807	10	37	in	in	ADP
bjp-38807	10	38	chinese	chinese	ADJ
bjp-38807	10	39	children	child	NOUN
bjp-38807	10	40	with	with	ADP
bjp-38807	10	41	advanced	advanced	ADJ
bjp-38807	10	42	neuroblastoma	neuroblastoma	NOUN
bjp-38807	10	43	.	.	PUNCT
bjp-38807	11	1	the	the	DET
bjp-38807	11	2	patients	patient	NOUN
bjp-38807	11	3	aged	age	VERB
bjp-38807	11	4	less	less	ADJ
bjp-38807	11	5	than	than	ADP
bjp-38807	11	6	16	16	NUM
bjp-38807	11	7	years	year	NOUN
bjp-38807	11	8	who	who	PRON
bjp-38807	11	9	were	be	AUX
bjp-38807	11	10	histologically	histologically	ADV
bjp-38807	11	11	diagnosed	diagnose	VERB
bjp-38807	11	12	with	with	ADP
bjp-38807	11	13	advanced	advanced	ADJ
bjp-38807	11	14	neuroblastoma	neuroblastoma	NOUN
bjp-38807	11	15	were	be	AUX
bjp-38807	11	16	enrolled	enrol	VERB
bjp-38807	11	17	and	and	CCONJ
bjp-38807	11	18	randomized	randomize	VERB
bjp-38807	11	19	to	to	PART
bjp-38807	11	20	receive	receive	VERB
bjp-38807	11	21	either	either	CCONJ
bjp-38807	11	22	regorafenib	regorafenib	NOUN
bjp-38807	11	23	plus	plus	CCONJ
bjp-38807	11	24	best	good	ADJ
bjp-38807	11	25	supportive	supportive	ADJ
bjp-38807	11	26	care	care	NOUN
bjp-38807	11	27	or	or	CCONJ
bjp-38807	11	28	dinutuximab	dinutuximab	NOUN
bjp-38807	11	29	plus	plus	CCONJ
bjp-38807	11	30	chemotherapy	chemotherapy	NOUN
bjp-38807	11	31	plus	plus	CCONJ
bjp-38807	11	32	best	good	ADJ
bjp-38807	11	33	supportive	supportive	ADJ
bjp-38807	11	34	care	care	NOUN
bjp-38807	11	35	in	in	ADP
bjp-38807	11	36	a	a	DET
bjp-38807	11	37	1:1	1:1	NUM
bjp-38807	11	38	ratio	ratio	NOUN
bjp-38807	11	39	.	.	PUNCT
bjp-38807	12	1	the	the	DET
bjp-38807	12	2	tumor	tumor	NOUN
bjp-38807	12	3	response	response	NOUN
bjp-38807	12	4	assessment	assessment	NOUN
bjp-38807	12	5	was	be	AUX
bjp-38807	12	6	made	make	VERB
bjp-38807	12	7	in	in	ADP
bjp-38807	12	8	accordance	accordance	NOUN
bjp-38807	12	9	with	with	ADP
bjp-38807	12	10	modified	modify	VERB
bjp-38807	12	11	international	international	ADJ
bjp-38807	12	12	neuroblastoma	neuroblastoma	ADJ
bjp-38807	12	13	response	response	NOUN
bjp-38807	12	14	criteria	criterion	NOUN
bjp-38807	12	15	.	.	PUNCT
bjp-38807	13	1	adverse	adverse	ADJ
bjp-38807	13	2	events	event	NOUN
bjp-38807	13	3	were	be	AUX
bjp-38807	13	4	also	also	ADV
bjp-38807	13	5	assessed	assess	VERB
bjp-38807	13	6	.	.	PUNCT
bjp-38807	14	1	regorafenib	regorafenib	NOUN
bjp-38807	14	2	showed	show	VERB
bjp-38807	14	3	prolonged	prolonged	ADJ
bjp-38807	14	4	overall	overall	ADJ
bjp-38807	14	5	survival	survival	NOUN
bjp-38807	14	6	and	and	CCONJ
bjp-38807	14	7	progressionfree	progressionfree	ADJ
bjp-38807	14	8	survival	survival	NOUN
bjp-38807	14	9	than	than	SCONJ
bjp-38807	14	10	who	who	PRON
bjp-38807	14	11	received	receive	VERB
bjp-38807	14	12	dinutuximab	dinutuximab	NOUN
bjp-38807	14	13	plus	plus	CCONJ
bjp-38807	14	14	chemotherapy	chemotherapy	NOUN
bjp-38807	14	15	(	(	PUNCT
bjp-38807	14	16	overall	overall	ADJ
bjp-38807	14	17	survival	survival	NOUN
bjp-38807	14	18	:	:	PUNCT
bjp-38807	14	19	median	median	NOUN
bjp-38807	14	20	32.3	32.3	NUM
bjp-38807	14	21	months	month	NOUN
bjp-38807	14	22	versus	versus	ADP
bjp-38807	14	23	27.2	27.2	NUM
bjp-38807	14	24	months	month	NOUN
bjp-38807	14	25	;	;	PUNCT
bjp-38807	14	26	hazard	hazard	NOUN
bjp-38807	14	27	ratio	ratio	NOUN
bjp-38807	14	28	=	=	NOUN
bjp-38807	14	29	0.45	0.45	NUM
bjp-38807	14	30	;	;	PUNCT
bjp-38807	14	31	95	95	NUM
bjp-38807	14	32	%	%	NOUN
bjp-38807	14	33	ci	ci	NOUN
bjp-38807	14	34	0.11	0.11	NUM
bjp-38807	14	35	-	-	SYM
bjp-38807	14	36	0.13	0.13	NUM
bjp-38807	14	37	,	,	PUNCT
bjp-38807	14	38	p<0.001	p<0.001	NOUN
bjp-38807	14	39	;	;	PUNCT
bjp-38807	14	40	progression	progression	NOUN
bjp-38807	14	41	-	-	PUNCT
bjp-38807	14	42	free	free	ADJ
bjp-38807	14	43	survival	survival	NOUN
bjp-38807	14	44	:	:	PUNCT
bjp-38807	14	45	stratified	stratify	VERB
bjp-38807	14	46	hazard	hazard	NOUN
bjp-38807	14	47	ratio	ratio	NOUN
bjp-38807	14	48	=	=	PROPN
bjp-38807	14	49	0.48	0.48	NUM
bjp-38807	14	50	;	;	PUNCT
bjp-38807	14	51	95	95	NUM
bjp-38807	14	52	%	%	NOUN
bjp-38807	14	53	ci	ci	NOUN
bjp-38807	14	54	0.11	0.11	NUM
bjp-38807	14	55	-	-	SYM
bjp-38807	14	56	0.14	0.14	NUM
bjp-38807	14	57	;	;	PUNCT
bjp-38807	14	58	p<0.01	p<0.01	PROPN
bjp-38807	14	59	)	)	PUNCT
bjp-38807	14	60	.	.	PUNCT
bjp-38807	15	1	moreover	moreover	ADV
bjp-38807	15	2	,	,	PUNCT
bjp-38807	15	3	the	the	DET
bjp-38807	15	4	overall	overall	ADJ
bjp-38807	15	5	response	response	NOUN
bjp-38807	15	6	rate	rate	NOUN
bjp-38807	15	7	was	be	AUX
bjp-38807	15	8	greater	great	ADJ
bjp-38807	15	9	in	in	ADP
bjp-38807	15	10	patients	patient	NOUN
bjp-38807	15	11	treated	treat	VERB
bjp-38807	15	12	with	with	ADP
bjp-38807	15	13	regorafenib	regorafenib	NOUN
bjp-38807	15	14	as	as	SCONJ
bjp-38807	15	15	compared	compare	VERB
bjp-38807	15	16	to	to	ADP
bjp-38807	15	17	dinutuximab	dinutuximab	NOUN
bjp-38807	15	18	group	group	NOUN
bjp-38807	15	19	.	.	PUNCT
bjp-38807	16	1	regorafenib	regorafenib	PROPN
bjp-38807	16	2	appears	appear	VERB
bjp-38807	16	3	efficacious	efficacious	ADJ
bjp-38807	16	4	and	and	CCONJ
bjp-38807	16	5	has	have	VERB
bjp-38807	16	6	a	a	DET
bjp-38807	16	7	manageable	manageable	ADJ
bjp-38807	16	8	safety	safety	NOUN
bjp-38807	16	9	profile	profile	NOUN
bjp-38807	16	10	in	in	ADP
bjp-38807	16	11	chinese	chinese	ADJ
bjp-38807	16	12	children	child	NOUN
bjp-38807	16	13	with	with	ADP
bjp-38807	16	14	advanced	advanced	ADJ
bjp-38807	16	15	neuroblastoma	neuroblastoma	NOUN
bjp-38807	16	16	.	.	PUNCT
bjp-38807	17	1	article	article	NOUN
bjp-38807	17	2	info	info	NOUN
bjp-38807	17	3	received	receive	VERB
bjp-38807	17	4	:	:	PUNCT
bjp-38807	17	5	20	20	NUM
bjp-38807	17	6	november	november	PROPN
bjp-38807	17	7	2018	2018	NUM
bjp-38807	17	8	accepted	accept	VERB
bjp-38807	17	9	:	:	PUNCT
bjp-38807	17	10	15	15	NUM
bjp-38807	17	11	december	december	PROPN
bjp-38807	17	12	2018	2018	NUM
bjp-38807	17	13	available	available	ADJ
bjp-38807	17	14	online	online	ADV
bjp-38807	17	15	:	:	PUNCT
bjp-38807	17	16	7	7	NUM
bjp-38807	17	17	february	february	PROPN
bjp-38807	17	18	2019	2019	NUM
bjp-38807	17	19	doi	doi	NOUN
bjp-38807	17	20	:	:	PUNCT
bjp-38807	17	21	10.3329	10.3329	NUM
bjp-38807	17	22	/	/	SYM
bjp-38807	17	23	bjp.v14i1.38807	bjp.v14i1.38807	PROPN
bjp-38807	17	24	cite	cite	VERB
bjp-38807	17	25	this	this	DET
bjp-38807	17	26	article	article	NOUN
bjp-38807	17	27	:	:	PUNCT
bjp-38807	17	28	dong	dong	PROPN
bjp-38807	17	29	k	k	PROPN
bjp-38807	17	30	,	,	PUNCT
bjp-38807	17	31	wang	wang	PROPN
bjp-38807	17	32	g	g	PROPN
bjp-38807	17	33	,	,	PUNCT
bjp-38807	17	34	wang	wang	PROPN
bjp-38807	17	35	zl	zl	PROPN
bjp-38807	17	36	,	,	PUNCT
bjp-38807	17	37	wang	wang	PROPN
bjp-38807	17	38	x.	x.	PROPN
bjp-38807	17	39	efficacy	efficacy	PROPN
bjp-38807	17	40	and	and	CCONJ
bjp-38807	17	41	safety	safety	NOUN
bjp-38807	17	42	of	of	ADP
bjp-38807	17	43	regorafenib	regorafenib	NOUN
bjp-38807	17	44	versus	versus	ADP
bjp-38807	17	45	dinutuximab	dinutuximab	NOUN
bjp-38807	17	46	with	with	ADP
bjp-38807	17	47	chemotherapy	chemotherapy	NOUN
bjp-38807	17	48	in	in	ADP
bjp-38807	17	49	chinese	chinese	ADJ
bjp-38807	17	50	children	child	NOUN
bjp-38807	17	51	with	with	ADP
bjp-38807	17	52	neuroblastoma	neuroblastoma	NOUN
bjp-38807	17	53	.	.	PUNCT
bjp-38807	18	1	bangladesh	bangladesh	PROPN
bjp-38807	18	2	j	j	PROPN
bjp-38807	18	3	pharmacol	pharmacol	PROPN
bjp-38807	18	4	.	.	PROPN
bjp-38807	19	1	2019	2019	NUM
bjp-38807	19	2	;	;	PUNCT
bjp-38807	20	1	14	14	NUM
bjp-38807	20	2	:	:	SYM
bjp-38807	20	3	32	32	NUM
bjp-38807	20	4	-	-	SYM
bjp-38807	20	5	35	35	NUM
bjp-38807	20	6	.	.	PUNCT
bjp-38807	20	7	efficacy	efficacy	NOUN
bjp-38807	20	8	and	and	CCONJ
bjp-38807	20	9	safety	safety	NOUN
bjp-38807	20	10	of	of	ADP
bjp-38807	20	11	regorafenib	regorafenib	NOUN
bjp-38807	20	12	versus	versus	ADP
bjp-38807	20	13	dinutuximab	dinutuximab	NOUN
bjp-38807	20	14	with	with	ADP
bjp-38807	20	15	chemotherapy	chemotherapy	NOUN
bjp-38807	20	16	in	in	ADP
bjp-38807	20	17	chinese	chinese	ADJ
bjp-38807	20	18	children	child	NOUN
bjp-38807	20	19	with	with	ADP
bjp-38807	20	20	neuroblastoma	neuroblastoma	ADJ
bjp-38807	20	21	kun	kun	PROPN
bjp-38807	20	22	dong	dong	PROPN
bjp-38807	20	23	,	,	PUNCT
bjp-38807	20	24	guan	guan	PROPN
bjp-38807	20	25	wang	wang	PROPN
bjp-38807	20	26	,	,	PUNCT
bjp-38807	20	27	zeng	zeng	PROPN
bjp-38807	20	28	liang	liang	PROPN
bjp-38807	20	29	wang	wang	PROPN
bjp-38807	20	30	and	and	CCONJ
bjp-38807	20	31	xueyan	xueyan	PROPN
bjp-38807	20	32	wang	wang	PROPN
bjp-38807	20	33	department	department	PROPN
bjp-38807	20	34	of	of	ADP
bjp-38807	20	35	neurosurgery	neurosurgery	NOUN
bjp-38807	20	36	,	,	PUNCT
bjp-38807	20	37	second	second	ADJ
bjp-38807	20	38	affiliated	affiliated	ADJ
bjp-38807	20	39	hospital	hospital	NOUN
bjp-38807	20	40	of	of	ADP
bjp-38807	20	41	tianjin	tianjin	PROPN
bjp-38807	20	42	university	university	PROPN
bjp-38807	20	43	of	of	ADP
bjp-38807	20	44	traditional	traditional	ADJ
bjp-38807	20	45	chinese	chinese	ADJ
bjp-38807	20	46	medicine	medicine	NOUN
bjp-38807	20	47	,	,	PUNCT
bjp-38807	20	48	tianjin	tianjin	PROPN
bjp-38807	20	49	300150	300150	NUM
bjp-38807	20	50	,	,	PUNCT
bjp-38807	20	51	china	china	PROPN
bjp-38807	20	52	.	.	PUNCT
bjp-38807	21	1	this	this	DET
bjp-38807	21	2	work	work	NOUN
bjp-38807	21	3	is	be	AUX
bjp-38807	21	4	licensed	license	VERB
bjp-38807	21	5	under	under	ADP
bjp-38807	21	6	a	a	DET
bjp-38807	21	7	creative	creative	ADJ
bjp-38807	21	8	commons	common	NOUN
bjp-38807	21	9	attribution	attribution	NOUN
bjp-38807	21	10	4.0	4.0	NUM
bjp-38807	21	11	license	license	NOUN
bjp-38807	21	12	.	.	PUNCT
bjp-38807	22	1	you	you	PRON
bjp-38807	22	2	are	be	AUX
bjp-38807	22	3	free	free	ADJ
bjp-38807	22	4	to	to	PART
bjp-38807	22	5	copy	copy	VERB
bjp-38807	22	6	,	,	PUNCT
bjp-38807	22	7	distribute	distribute	VERB
bjp-38807	22	8	and	and	CCONJ
bjp-38807	22	9	perform	perform	VERB
bjp-38807	22	10	the	the	DET
bjp-38807	22	11	work	work	NOUN
bjp-38807	22	12	.	.	PUNCT
bjp-38807	23	1	you	you	PRON
bjp-38807	23	2	must	must	AUX
bjp-38807	23	3	attribute	attribute	VERB
bjp-38807	23	4	the	the	DET
bjp-38807	23	5	work	work	NOUN
bjp-38807	23	6	in	in	ADP
bjp-38807	23	7	the	the	DET
bjp-38807	23	8	manner	manner	NOUN
bjp-38807	23	9	specified	specify	VERB
bjp-38807	23	10	by	by	ADP
bjp-38807	23	11	the	the	DET
bjp-38807	23	12	author	author	NOUN
bjp-38807	23	13	or	or	CCONJ
bjp-38807	23	14	licensor	licensor	NOUN
bjp-38807	23	15	.	.	PUNCT
bjp-38807	24	1	a	a	DET
bjp-38807	24	2	journal	journal	NOUN
bjp-38807	24	3	of	of	ADP
bjp-38807	24	4	the	the	DET
bjp-38807	24	5	bangladesh	bangladesh	NOUN
bjp-38807	24	6	pharmacological	pharmacological	ADJ
bjp-38807	24	7	society	society	NOUN
bjp-38807	24	8	(	(	PUNCT
bjp-38807	24	9	bdps	bdps	NOUN
bjp-38807	24	10	)	)	PUNCT
bjp-38807	24	11	bangladesh	bangladesh	PROPN
bjp-38807	24	12	j	j	PROPN
bjp-38807	24	13	pharmacol	pharmacol	PROPN
bjp-38807	24	14	2019	2019	NUM
bjp-38807	24	15	;	;	PUNCT
bjp-38807	24	16	14	14	NUM
bjp-38807	24	17	:	:	SYM
bjp-38807	24	18	32	32	NUM
bjp-38807	24	19	-	-	SYM
bjp-38807	24	20	35	35	NUM
bjp-38807	24	21	journal	journal	NOUN
bjp-38807	24	22	homepage	homepage	NOUN
bjp-38807	24	23	:	:	PUNCT
bjp-38807	24	24	www.banglajol.info	www.banglajol.info	PROPN
bjp-38807	24	25	abstracted	abstract	VERB
bjp-38807	24	26	/	/	SYM
bjp-38807	24	27	indexed	index	VERB
bjp-38807	24	28	in	in	ADP
bjp-38807	24	29	academic	academic	ADJ
bjp-38807	24	30	search	search	NOUN
bjp-38807	24	31	complete	complete	ADJ
bjp-38807	24	32	,	,	PUNCT
bjp-38807	24	33	agroforestry	agroforestry	NOUN
bjp-38807	24	34	abstracts	abstract	NOUN
bjp-38807	24	35	,	,	PUNCT
bjp-38807	24	36	asia	asia	PROPN
bjp-38807	24	37	journals	journal	NOUN
bjp-38807	24	38	online	online	ADV
bjp-38807	24	39	,	,	PUNCT
bjp-38807	24	40	bangladesh	bangladesh	NOUN
bjp-38807	24	41	journals	journal	NOUN
bjp-38807	24	42	online	online	ADV
bjp-38807	24	43	,	,	PUNCT
bjp-38807	24	44	biological	biological	ADJ
bjp-38807	24	45	abstracts	abstract	NOUN
bjp-38807	24	46	,	,	PUNCT
bjp-38807	24	47	biosis	biosis	NOUN
bjp-38807	24	48	previews	preview	NOUN
bjp-38807	24	49	,	,	PUNCT
bjp-38807	24	50	cab	cab	NOUN
bjp-38807	24	51	abstracts	abstract	NOUN
bjp-38807	24	52	,	,	PUNCT
bjp-38807	24	53	current	current	ADJ
bjp-38807	24	54	abstracts	abstract	NOUN
bjp-38807	24	55	,	,	PUNCT
bjp-38807	24	56	directory	directory	NOUN
bjp-38807	24	57	of	of	ADP
bjp-38807	24	58	open	open	ADJ
bjp-38807	24	59	access	access	NOUN
bjp-38807	24	60	journals	journal	NOUN
bjp-38807	24	61	,	,	PUNCT
bjp-38807	24	62	embase	embase	NOUN
bjp-38807	24	63	/	/	SYM
bjp-38807	24	64	excerpta	excerpta	NOUN
bjp-38807	24	65	medica	medica	NOUN
bjp-38807	24	66	,	,	PUNCT
bjp-38807	24	67	global	global	ADJ
bjp-38807	24	68	health	health	NOUN
bjp-38807	24	69	,	,	PUNCT
bjp-38807	24	70	google	google	PROPN
bjp-38807	24	71	scholar	scholar	NOUN
bjp-38807	24	72	,	,	PUNCT
bjp-38807	24	73	hinari	hinari	X
bjp-38807	24	74	(	(	PUNCT
bjp-38807	24	75	who	who	PRON
bjp-38807	24	76	)	)	PUNCT
bjp-38807	24	77	,	,	PUNCT
bjp-38807	24	78	international	international	ADJ
bjp-38807	24	79	pharmaceutical	pharmaceutical	ADJ
bjp-38807	24	80	abstracts	abstract	NOUN
bjp-38807	24	81	,	,	PUNCT
bjp-38807	24	82	open	open	ADJ
bjp-38807	24	83	j	j	PROPN
bjp-38807	24	84	-	-	PUNCT
bjp-38807	24	85	gate	gate	NOUN
bjp-38807	24	86	,	,	PUNCT
bjp-38807	24	87	science	science	NOUN
bjp-38807	24	88	citation	citation	NOUN
bjp-38807	24	89	index	index	NOUN
bjp-38807	24	90	expanded	expand	VERB
bjp-38807	24	91	,	,	PUNCT
bjp-38807	24	92	scopus	scopus	NOUN
bjp-38807	24	93	and	and	CCONJ
bjp-38807	24	94	social	social	ADJ
bjp-38807	24	95	sciences	sciences	PROPN
bjp-38807	24	96	citation	citation	NOUN
bjp-38807	24	97	index	index	NOUN
bjp-38807	24	98	issn	issn	PROPN
bjp-38807	24	99	:	:	PUNCT
bjp-38807	24	100	1991	1991	NUM
bjp-38807	24	101	-	-	SYM
bjp-38807	24	102	0088	0088	NUM
bjp-38807	25	1	c	c	NOUN
bjp-38807	25	2	lin	lin	PROPN
bjp-38807	25	3	ic	ic	PROPN
bjp-38807	25	4	al	al	PROPN
bjp-38807	25	5	t	t	PROPN
bjp-38807	25	6	ria	ria	PROPN
bjp-38807	25	7	l	l	PROPN
bjp-38807	25	8	growth	growth	NOUN
bjp-38807	25	9	in	in	ADP
bjp-38807	25	10	pre	pre	ADJ
bjp-38807	25	11	-	-	ADJ
bjp-38807	25	12	clinical	clinical	ADJ
bjp-38807	25	13	model	model	NOUN
bjp-38807	25	14	.	.	PUNCT
bjp-38807	26	1	however	however	ADV
bjp-38807	26	2	,	,	PUNCT
bjp-38807	26	3	no	no	DET
bjp-38807	26	4	clinical	clinical	ADJ
bjp-38807	26	5	studies	study	NOUN
bjp-38807	26	6	have	have	AUX
bjp-38807	26	7	been	be	AUX
bjp-38807	26	8	conducted	conduct	VERB
bjp-38807	26	9	to	to	PART
bjp-38807	26	10	evaluate	evaluate	VERB
bjp-38807	26	11	the	the	DET
bjp-38807	26	12	efficacy	efficacy	NOUN
bjp-38807	26	13	and	and	CCONJ
bjp-38807	26	14	safety	safety	NOUN
bjp-38807	26	15	of	of	ADP
bjp-38807	26	16	regorafenib	regorafenib	NOUN
bjp-38807	26	17	in	in	ADP
bjp-38807	26	18	children	child	NOUN
bjp-38807	26	19	with	with	ADP
bjp-38807	26	20	neuroblastoma	neuroblastoma	NOUN
bjp-38807	26	21	.	.	PUNCT
bjp-38807	27	1	regorafenib	regorafenib	PROPN
bjp-38807	27	2	is	be	AUX
bjp-38807	27	3	selective	selective	ADJ
bjp-38807	27	4	against	against	ADP
bjp-38807	27	5	vegfr1	vegfr1	NOUN
bjp-38807	27	6	,	,	PUNCT
bjp-38807	27	7	2	2	NUM
bjp-38807	27	8	,	,	PUNCT
bjp-38807	27	9	and	and	CCONJ
bjp-38807	28	1	3	3	X
bjp-38807	28	2	.	.	X
bjp-38807	29	1	it	it	PRON
bjp-38807	29	2	shows	show	VERB
bjp-38807	29	3	an	an	DET
bjp-38807	29	4	acceptable	acceptable	ADJ
bjp-38807	29	5	safety	safety	NOUN
bjp-38807	29	6	profile	profile	NOUN
bjp-38807	29	7	and	and	CCONJ
bjp-38807	29	8	evidence	evidence	NOUN
bjp-38807	29	9	of	of	ADP
bjp-38807	29	10	antitumor	antitumor	PROPN
bjp-38807	29	11	activity	activity	NOUN
bjp-38807	29	12	in	in	ADP
bjp-38807	29	13	patient	patient	NOUN
bjp-38807	29	14	with	with	ADP
bjp-38807	29	15	advanced	advanced	ADJ
bjp-38807	29	16	solid	solid	ADJ
bjp-38807	29	17	tumor	tumor	NOUN
bjp-38807	29	18	in	in	ADP
bjp-38807	29	19	several	several	ADJ
bjp-38807	29	20	oncology	oncology	NOUN
bjp-38807	29	21	clinical	clinical	ADJ
bjp-38807	29	22	studies	study	NOUN
bjp-38807	29	23	(	(	PUNCT
bjp-38807	29	24	lacouture	lacouture	NOUN
bjp-38807	29	25	et	et	PROPN
bjp-38807	29	26	al	al	PROPN
bjp-38807	29	27	.	.	PROPN
bjp-38807	29	28	,	,	PUNCT
bjp-38807	29	29	2008	2008	NUM
bjp-38807	29	30	;	;	PUNCT
bjp-38807	29	31	kamba	kamba	NOUN
bjp-38807	29	32	and	and	CCONJ
bjp-38807	29	33	mcdonald	mcdonald	PROPN
bjp-38807	29	34	,	,	PUNCT
bjp-38807	29	35	2007	2007	NUM
bjp-38807	29	36	)	)	PUNCT
bjp-38807	29	37	.	.	PUNCT
bjp-38807	30	1	in	in	ADP
bjp-38807	30	2	the	the	DET
bjp-38807	30	3	present	present	ADJ
bjp-38807	30	4	study	study	NOUN
bjp-38807	30	5	,	,	PUNCT
bjp-38807	30	6	we	we	PRON
bjp-38807	30	7	hypothesized	hypothesize	VERB
bjp-38807	30	8	that	that	SCONJ
bjp-38807	30	9	regorafenib	regorafenib	NOUN
bjp-38807	30	10	demonstrated	demonstrate	VERB
bjp-38807	30	11	a	a	DET
bjp-38807	30	12	significant	significant	ADJ
bjp-38807	30	13	and	and	CCONJ
bjp-38807	30	14	clinically	clinically	ADV
bjp-38807	30	15	benefit	benefit	VERB
bjp-38807	30	16	in	in	ADP
bjp-38807	30	17	terms	term	NOUN
bjp-38807	30	18	of	of	ADP
bjp-38807	30	19	overall	overall	ADJ
bjp-38807	30	20	survival	survival	NOUN
bjp-38807	30	21	in	in	ADP
bjp-38807	30	22	chinese	chinese	ADJ
bjp-38807	30	23	children	child	NOUN
bjp-38807	30	24	with	with	ADP
bjp-38807	30	25	neuroblastoma	neuroblastoma	NOUN
bjp-38807	30	26	.	.	PUNCT
bjp-38807	31	1	efficacy	efficacy	NOUN
bjp-38807	31	2	of	of	ADP
bjp-38807	31	3	regorafenib	regorafenib	PROPN
bjp-38807	31	4	was	be	AUX
bjp-38807	31	5	compared	compare	VERB
bjp-38807	31	6	to	to	AUX
bjp-38807	31	7	dinutuximab	dinutuximab	VERB
bjp-38807	31	8	.	.	PUNCT
bjp-38807	32	1	materials	material	NOUN
bjp-38807	32	2	and	and	CCONJ
bjp-38807	32	3	methods	method	NOUN
bjp-38807	32	4	study	study	NOUN
bjp-38807	32	5	design	design	NOUN
bjp-38807	32	6	and	and	CCONJ
bjp-38807	32	7	participants	participant	NOUN
bjp-38807	32	8	this	this	PRON
bjp-38807	32	9	is	be	AUX
bjp-38807	32	10	a	a	DET
bjp-38807	32	11	preliminary	preliminary	ADJ
bjp-38807	32	12	study	study	NOUN
bjp-38807	32	13	comparing	compare	VERB
bjp-38807	32	14	regorafenib	regorafenib	NOUN
bjp-38807	32	15	versus	versus	ADP
bjp-38807	32	16	dinutuximab	dinutuximab	NOUN
bjp-38807	32	17	in	in	ADP
bjp-38807	32	18	chinese	chinese	ADJ
bjp-38807	32	19	children	child	NOUN
bjp-38807	32	20	with	with	ADP
bjp-38807	32	21	advanced	advanced	ADJ
bjp-38807	32	22	neuroblastoma	neuroblastoma	NOUN
bjp-38807	32	23	.	.	PUNCT
bjp-38807	33	1	the	the	DET
bjp-38807	33	2	overall	overall	ADJ
bjp-38807	33	3	safety	safety	NOUN
bjp-38807	33	4	profile	profile	NOUN
bjp-38807	33	5	of	of	ADP
bjp-38807	33	6	regorafenib	regorafenib	NOUN
bjp-38807	33	7	was	be	AUX
bjp-38807	33	8	assessed	assess	VERB
bjp-38807	33	9	.	.	PUNCT
bjp-38807	34	1	in	in	ADP
bjp-38807	34	2	patients	patient	NOUN
bjp-38807	34	3	who	who	PRON
bjp-38807	34	4	had	have	VERB
bjp-38807	34	5	karnofsky	karnofsky	ADJ
bjp-38807	34	6	/	/	SYM
bjp-38807	34	7	lansky	lansky	PROPN
bjp-38807	34	8	scores	score	VERB
bjp-38807	34	9	less	less	ADJ
bjp-38807	34	10	than	than	ADP
bjp-38807	34	11	or	or	CCONJ
bjp-38807	34	12	equal	equal	ADJ
bjp-38807	34	13	to	to	ADP
bjp-38807	34	14	50	50	NUM
bjp-38807	34	15	%	%	NOUN
bjp-38807	34	16	,	,	PUNCT
bjp-38807	34	17	with	with	ADP
bjp-38807	34	18	age	age	NOUN
bjp-38807	34	19	less	less	ADJ
bjp-38807	34	20	than	than	ADP
bjp-38807	34	21	16	16	NUM
bjp-38807	34	22	years	year	NOUN
bjp-38807	34	23	who	who	PRON
bjp-38807	34	24	histologically	histologically	ADV
bjp-38807	34	25	and/or	and/or	CCONJ
bjp-38807	34	26	cytological	cytological	ADJ
bjp-38807	34	27	were	be	AUX
bjp-38807	34	28	diagnosed	diagnose	VERB
bjp-38807	34	29	with	with	ADP
bjp-38807	34	30	advanced	advanced	ADJ
bjp-38807	34	31	neuroblastoma	neuroblastoma	NOUN
bjp-38807	34	32	,	,	PUNCT
bjp-38807	34	33	with	with	ADP
bjp-38807	34	34	increased	increase	VERB
bjp-38807	34	35	urine	urine	NOUN
bjp-38807	34	36	level	level	NOUN
bjp-38807	34	37	of	of	ADP
bjp-38807	34	38	catecholamine	catecholamine	NOUN
bjp-38807	34	39	were	be	AUX
bjp-38807	34	40	enrolled	enrol	VERB
bjp-38807	34	41	.	.	PUNCT
bjp-38807	35	1	the	the	DET
bjp-38807	35	2	patient	patient	NOUN
bjp-38807	35	3	with	with	ADP
bjp-38807	35	4	insufficient	insufficient	ADJ
bjp-38807	35	5	response	response	NOUN
bjp-38807	35	6	after	after	ADP
bjp-38807	35	7	four	four	NUM
bjp-38807	35	8	cycles	cycle	NOUN
bjp-38807	35	9	of	of	ADP
bjp-38807	35	10	more	more	ADJ
bjp-38807	35	11	than	than	ADP
bjp-38807	35	12	2	2	NUM
bjp-38807	35	13	chemotherapeutic	chemotherapeutic	ADJ
bjp-38807	35	14	agents	agent	NOUN
bjp-38807	35	15	,	,	PUNCT
bjp-38807	35	16	that	that	PRON
bjp-38807	35	17	included	include	VERB
bjp-38807	35	18	alkylating	alkylating	NOUN
bjp-38807	35	19	agents	agent	NOUN
bjp-38807	35	20	and	and	CCONJ
bjp-38807	35	21	platinum	platinum	NOUN
bjp-38807	35	22	-	-	PUNCT
bjp-38807	35	23	containing	contain	VERB
bjp-38807	35	24	chemotherapeutic	chemotherapeutic	ADJ
bjp-38807	35	25	agents	agent	NOUN
bjp-38807	35	26	were	be	AUX
bjp-38807	35	27	also	also	ADV
bjp-38807	35	28	eligible	eligible	ADJ
bjp-38807	35	29	for	for	ADP
bjp-38807	35	30	the	the	DET
bjp-38807	35	31	enrollment	enrollment	NOUN
bjp-38807	35	32	.	.	PUNCT
bjp-38807	36	1	patients	patient	NOUN
bjp-38807	36	2	who	who	PRON
bjp-38807	36	3	had	have	AUX
bjp-38807	36	4	previously	previously	ADV
bjp-38807	36	5	received	receive	VERB
bjp-38807	36	6	any	any	DET
bjp-38807	36	7	vegfr	vegfr	ADJ
bjp-38807	36	8	inhibitors	inhibitor	NOUN
bjp-38807	36	9	or	or	CCONJ
bjp-38807	36	10	had	have	VERB
bjp-38807	36	11	other	other	ADJ
bjp-38807	36	12	uncontrolled	uncontrolled	ADJ
bjp-38807	36	13	medical	medical	ADJ
bjp-38807	36	14	disorders	disorder	NOUN
bjp-38807	36	15	were	be	AUX
bjp-38807	36	16	excluded	exclude	VERB
bjp-38807	36	17	.	.	PUNCT
bjp-38807	37	1	the	the	DET
bjp-38807	37	2	patients	patient	NOUN
bjp-38807	37	3	who	who	PRON
bjp-38807	37	4	were	be	AUX
bjp-38807	37	5	previously	previously	ADV
bjp-38807	37	6	treated	treat	VERB
bjp-38807	37	7	with	with	ADP
bjp-38807	37	8	anti	anti	ADJ
bjp-38807	37	9	-	-	ADJ
bjp-38807	37	10	epidermal	epidermal	ADJ
bjp-38807	37	11	growth	growth	NOUN
bjp-38807	37	12	factor	factor	NOUN
bjp-38807	37	13	receptor	receptor	NOUN
bjp-38807	37	14	or	or	CCONJ
bjp-38807	37	15	vegf	vegf	NOUN
bjp-38807	37	16	agents	agent	NOUN
bjp-38807	37	17	were	be	AUX
bjp-38807	37	18	allowed	allow	VERB
bjp-38807	37	19	but	but	CCONJ
bjp-38807	37	20	were	be	AUX
bjp-38807	37	21	not	not	PART
bjp-38807	37	22	mandatory	mandatory	ADJ
bjp-38807	37	23	.	.	PUNCT
bjp-38807	38	1	in	in	ADP
bjp-38807	38	2	this	this	DET
bjp-38807	38	3	study	study	NOUN
bjp-38807	38	4	,	,	PUNCT
bjp-38807	38	5	a	a	DET
bjp-38807	38	6	total	total	NOUN
bjp-38807	38	7	of	of	ADP
bjp-38807	38	8	65	65	NUM
bjp-38807	38	9	patients	patient	NOUN
bjp-38807	38	10	were	be	AUX
bjp-38807	38	11	screened	screen	VERB
bjp-38807	38	12	,	,	PUNCT
bjp-38807	38	13	and	and	CCONJ
bjp-38807	38	14	60	60	NUM
bjp-38807	38	15	patients	patient	NOUN
bjp-38807	38	16	were	be	AUX
bjp-38807	38	17	randomized	randomize	VERB
bjp-38807	38	18	to	to	PART
bjp-38807	38	19	receive	receive	VERB
bjp-38807	38	20	either	either	CCONJ
bjp-38807	38	21	regorafenib	regorafenib	NOUN
bjp-38807	38	22	plus	plus	CCONJ
bjp-38807	38	23	best	good	ADJ
bjp-38807	38	24	supportive	supportive	ADJ
bjp-38807	38	25	care	care	NOUN
bjp-38807	38	26	(	(	PUNCT
bjp-38807	38	27	n=30	n=30	NOUN
bjp-38807	38	28	)	)	PUNCT
bjp-38807	38	29	or	or	CCONJ
bjp-38807	38	30	dinutuximab	dinutuximab	NOUN
bjp-38807	38	31	plus	plus	CCONJ
bjp-38807	38	32	chemotherapy	chemotherapy	NOUN
bjp-38807	38	33	(	(	PUNCT
bjp-38807	38	34	irinotecan	irinotecan	NOUN
bjp-38807	38	35	and	and	CCONJ
bjp-38807	38	36	temozolomide	temozolomide	NOUN
bjp-38807	38	37	)	)	PUNCT
bjp-38807	38	38	plus	plus	CCONJ
bjp-38807	38	39	best	good	ADJ
bjp-38807	38	40	supportive	supportive	ADJ
bjp-38807	38	41	care	care	NOUN
bjp-38807	38	42	(	(	PUNCT
bjp-38807	38	43	n=30	n=30	NOUN
bjp-38807	38	44	)	)	PUNCT
bjp-38807	38	45	between	between	ADP
bjp-38807	38	46	january	january	PROPN
bjp-38807	38	47	2016	2016	NUM
bjp-38807	38	48	and	and	CCONJ
bjp-38807	38	49	december	december	PROPN
bjp-38807	38	50	2017	2017	NUM
bjp-38807	38	51	.	.	PUNCT
bjp-38807	39	1	study	study	NOUN
bjp-38807	39	2	treatment	treatment	NOUN
bjp-38807	39	3	in	in	ADP
bjp-38807	39	4	this	this	DET
bjp-38807	39	5	study	study	NOUN
bjp-38807	39	6	,	,	PUNCT
bjp-38807	39	7	the	the	DET
bjp-38807	39	8	eligible	eligible	ADJ
bjp-38807	39	9	participants	participant	NOUN
bjp-38807	39	10	were	be	AUX
bjp-38807	39	11	randomized	randomize	VERB
bjp-38807	39	12	to	to	PART
bjp-38807	39	13	receive	receive	VERB
bjp-38807	39	14	either	either	CCONJ
bjp-38807	39	15	regorafenib	regorafenib	NOUN
bjp-38807	39	16	plus	plus	CCONJ
bjp-38807	39	17	best	good	ADJ
bjp-38807	39	18	supportive	supportive	ADJ
bjp-38807	39	19	care	care	NOUN
bjp-38807	39	20	or	or	CCONJ
bjp-38807	39	21	dinutuximab	dinutuximab	NOUN
bjp-38807	39	22	plus	plus	CCONJ
bjp-38807	39	23	chemotherapy	chemotherapy	NOUN
bjp-38807	39	24	(	(	PUNCT
bjp-38807	39	25	irinotecan	irinotecan	NOUN
bjp-38807	39	26	and	and	CCONJ
bjp-38807	39	27	temozolomide	temozolomide	NOUN
bjp-38807	39	28	)	)	PUNCT
bjp-38807	39	29	plus	plus	CCONJ
bjp-38807	39	30	best	good	ADJ
bjp-38807	39	31	supportive	supportive	ADJ
bjp-38807	39	32	care	care	NOUN
bjp-38807	39	33	in	in	ADP
bjp-38807	39	34	a	a	DET
bjp-38807	39	35	1:1	1:1	NUM
bjp-38807	39	36	ratio	ratio	NOUN
bjp-38807	39	37	.	.	PUNCT
bjp-38807	40	1	the	the	DET
bjp-38807	40	2	participants	participant	NOUN
bjp-38807	40	3	of	of	ADP
bjp-38807	40	4	the	the	DET
bjp-38807	40	5	regorafenib	regorafenib	PROPN
bjp-38807	40	6	group	group	NOUN
bjp-38807	40	7	received	receive	VERB
bjp-38807	40	8	regorafenib	regorafenib	NOUN
bjp-38807	40	9	160	160	NUM
bjp-38807	40	10	mg	mg	PROPN
bjp-38807	40	11	taken	take	VERB
bjp-38807	40	12	orally	orally	ADV
bjp-38807	40	13	once	once	ADV
bjp-38807	40	14	daily	daily	ADV
bjp-38807	40	15	for	for	ADP
bjp-38807	40	16	the	the	DET
bjp-38807	40	17	first	first	ADJ
bjp-38807	40	18	21	21	NUM
bjp-38807	40	19	days	day	NOUN
bjp-38807	40	20	of	of	ADP
bjp-38807	40	21	each	each	DET
bjp-38807	40	22	28	28	NUM
bjp-38807	40	23	-	-	PUNCT
bjp-38807	40	24	day	day	NOUN
bjp-38807	40	25	cycle	cycle	NOUN
bjp-38807	40	26	.	.	PUNCT
bjp-38807	41	1	dinutuximab	dinutuximab	NOUN
bjp-38807	41	2	(	(	PUNCT
bjp-38807	41	3	25	25	NUM
bjp-38807	41	4	mg	mg	NOUN
bjp-38807	41	5	per	per	ADP
bjp-38807	41	6	day	day	NOUN
bjp-38807	41	7	)	)	PUNCT
bjp-38807	41	8	was	be	AUX
bjp-38807	41	9	administered	administer	VERB
bjp-38807	41	10	as	as	ADP
bjp-38807	41	11	intravenous	intravenous	ADJ
bjp-38807	41	12	infusion	infusion	NOUN
bjp-38807	41	13	along	along	ADP
bjp-38807	41	14	with	with	ADP
bjp-38807	41	15	oral	oral	ADJ
bjp-38807	41	16	temozolomide	temozolomide	NOUN
bjp-38807	41	17	(	(	PUNCT
bjp-38807	41	18	100	100	NUM
bjp-38807	41	19	mg	mg	ADP
bjp-38807	41	20	per	per	ADP
bjp-38807	41	21	day	day	NOUN
bjp-38807	41	22	)	)	PUNCT
bjp-38807	41	23	and	and	CCONJ
bjp-38807	41	24	irinotecan	irinotecan	NOUN
bjp-38807	41	25	(	(	PUNCT
bjp-38807	41	26	50	50	NUM
bjp-38807	41	27	mg	mg	NOUN
bjp-38807	41	28	per	per	ADP
bjp-38807	41	29	day	day	NOUN
bjp-38807	41	30	)	)	PUNCT
bjp-38807	41	31	intravenously	intravenously	ADV
bjp-38807	41	32	.	.	PUNCT
bjp-38807	42	1	all	all	DET
bjp-38807	42	2	randomized	randomized	ADJ
bjp-38807	42	3	patients	patient	NOUN
bjp-38807	42	4	received	receive	VERB
bjp-38807	42	5	either	either	CCONJ
bjp-38807	42	6	regorafenib	regorafenib	NOUN
bjp-38807	42	7	plus	plus	CCONJ
bjp-38807	42	8	best	good	ADJ
bjp-38807	42	9	supportive	supportive	ADJ
bjp-38807	42	10	care	care	NOUN
bjp-38807	42	11	or	or	CCONJ
bjp-38807	42	12	dinutuximab	dinutuximab	NOUN
bjp-38807	42	13	plus	plus	CCONJ
bjp-38807	42	14	chemotherapy	chemotherapy	NOUN
bjp-38807	42	15	(	(	PUNCT
bjp-38807	42	16	irinotecan	irinotecan	NOUN
bjp-38807	42	17	and	and	CCONJ
bjp-38807	42	18	temozolomide	temozolomide	NOUN
bjp-38807	42	19	)	)	PUNCT
bjp-38807	42	20	plus	plus	CCONJ
bjp-38807	42	21	best	good	ADJ
bjp-38807	42	22	supportive	supportive	ADJ
bjp-38807	42	23	care	care	NOUN
bjp-38807	42	24	until	until	ADP
bjp-38807	42	25	discontinuation	discontinuation	NOUN
bjp-38807	42	26	due	due	ADP
bjp-38807	42	27	to	to	ADP
bjp-38807	42	28	intolerable	intolerable	ADJ
bjp-38807	42	29	toxicity	toxicity	NOUN
bjp-38807	42	30	or	or	CCONJ
bjp-38807	42	31	tumor	tumor	NOUN
bjp-38807	42	32	progression	progression	NOUN
bjp-38807	42	33	or	or	CCONJ
bjp-38807	42	34	patient	patient	NOUN
bjp-38807	42	35	and	and	CCONJ
bjp-38807	42	36	investigator	investigator	NOUN
bjp-38807	42	37	decision	decision	NOUN
bjp-38807	42	38	to	to	PART
bjp-38807	42	39	stop	stop	VERB
bjp-38807	42	40	the	the	DET
bjp-38807	42	41	treatment	treatment	NOUN
bjp-38807	42	42	or	or	CCONJ
bjp-38807	42	43	death	death	NOUN
bjp-38807	42	44	.	.	PUNCT
bjp-38807	43	1	efficacy	efficacy	NOUN
bjp-38807	43	2	and	and	CCONJ
bjp-38807	43	3	safety	safety	NOUN
bjp-38807	43	4	assessment	assessment	NOUN
bjp-38807	43	5	tumor	tumor	NOUN
bjp-38807	43	6	response	response	NOUN
bjp-38807	43	7	assessment	assessment	NOUN
bjp-38807	43	8	was	be	AUX
bjp-38807	43	9	conducted	conduct	VERB
bjp-38807	43	10	every	every	DET
bjp-38807	43	11	8	8	NUM
bjp-38807	43	12	weeks	week	NOUN
bjp-38807	43	13	until	until	ADP
bjp-38807	43	14	the	the	DET
bjp-38807	43	15	disease	disease	NOUN
bjp-38807	43	16	progression	progression	NOUN
bjp-38807	43	17	in	in	ADP
bjp-38807	43	18	accordance	accordance	NOUN
bjp-38807	43	19	with	with	ADP
bjp-38807	43	20	the	the	DET
bjp-38807	43	21	inr	inr	PROPN
bjp-38807	43	22	criteria	criterion	NOUN
bjp-38807	43	23	(	(	PUNCT
bjp-38807	43	24	modified	modify	VERB
bjp-38807	43	25	international	international	ADJ
bjp-38807	43	26	neuroblastoma	neuroblastoma	ADJ
bjp-38807	43	27	response	response	NOUN
bjp-38807	43	28	criteria	criterion	NOUN
bjp-38807	43	29	)	)	PUNCT
bjp-38807	43	30	,	,	PUNCT
bjp-38807	43	31	using	use	VERB
bjp-38807	43	32	computed	compute	VERB
bjp-38807	43	33	tomography	tomography	NOUN
bjp-38807	43	34	and/or	and/or	CCONJ
bjp-38807	43	35	magnetic	magnetic	ADJ
bjp-38807	43	36	resonance	resonance	NOUN
bjp-38807	43	37	imaging	imaging	NOUN
bjp-38807	43	38	evaluations	evaluation	NOUN
bjp-38807	43	39	to	to	PART
bjp-38807	43	40	assess	assess	VERB
bjp-38807	43	41	the	the	DET
bjp-38807	43	42	overall	overall	ADJ
bjp-38807	43	43	response	response	NOUN
bjp-38807	43	44	.	.	PUNCT
bjp-38807	44	1	the	the	DET
bjp-38807	44	2	patients	patient	NOUN
bjp-38807	44	3	with	with	ADP
bjp-38807	44	4	partial	partial	ADJ
bjp-38807	44	5	or	or	CCONJ
bjp-38807	44	6	complete	complete	ADJ
bjp-38807	44	7	response	response	NOUN
bjp-38807	44	8	were	be	AUX
bjp-38807	44	9	defined	define	VERB
bjp-38807	44	10	as	as	ADP
bjp-38807	44	11	responders	responder	NOUN
bjp-38807	44	12	.	.	PUNCT
bjp-38807	45	1	the	the	DET
bjp-38807	45	2	number	number	NOUN
bjp-38807	45	3	(	(	PUNCT
bjp-38807	45	4	percentage	percentage	NOUN
bjp-38807	45	5	)	)	PUNCT
bjp-38807	45	6	of	of	ADP
bjp-38807	45	7	patients	patient	NOUN
bjp-38807	45	8	with	with	ADP
bjp-38807	45	9	partial	partial	ADJ
bjp-38807	45	10	response	response	NOUN
bjp-38807	45	11	,	,	PUNCT
bjp-38807	45	12	complete	complete	ADJ
bjp-38807	45	13	response	response	NOUN
bjp-38807	45	14	,	,	PUNCT
bjp-38807	45	15	stable	stable	ADJ
bjp-38807	45	16	disease	disease	NOUN
bjp-38807	45	17	and	and	CCONJ
bjp-38807	45	18	progressive	progressive	ADJ
bjp-38807	45	19	disease	disease	NOUN
bjp-38807	45	20	were	be	AUX
bjp-38807	45	21	identified	identify	VERB
bjp-38807	45	22	as	as	ADP
bjp-38807	45	23	per	per	ADP
bjp-38807	45	24	the	the	DET
bjp-38807	45	25	standard	standard	ADJ
bjp-38807	45	26	definition	definition	NOUN
bjp-38807	45	27	.	.	PUNCT
bjp-38807	46	1	the	the	DET
bjp-38807	46	2	overall	overall	ADJ
bjp-38807	46	3	survival	survival	NOUN
bjp-38807	46	4	and	and	CCONJ
bjp-38807	46	5	progression	progression	NOUN
bjp-38807	46	6	-	-	PUNCT
bjp-38807	46	7	free	free	ADJ
bjp-38807	46	8	survival	survival	NOUN
bjp-38807	46	9	were	be	AUX
bjp-38807	46	10	calculated	calculate	VERB
bjp-38807	46	11	.	.	PUNCT
bjp-38807	47	1	adverse	adverse	ADJ
bjp-38807	47	2	events	event	NOUN
bjp-38807	47	3	were	be	AUX
bjp-38807	47	4	recorded	record	VERB
bjp-38807	47	5	using	use	VERB
bjp-38807	47	6	ctcae	ctcae	PROPN
bjp-38807	47	7	version	version	NOUN
bjp-38807	47	8	4.03	4.03	NUM
bjp-38807	47	9	,	,	PUNCT
bjp-38807	47	10	and	and	CCONJ
bjp-38807	47	11	recorded	record	VERB
bjp-38807	47	12	throughout	throughout	ADP
bjp-38807	47	13	the	the	DET
bjp-38807	47	14	study	study	NOUN
bjp-38807	47	15	period	period	NOUN
bjp-38807	47	16	.	.	PUNCT
bjp-38807	48	1	standard	standard	ADJ
bjp-38807	48	2	laboratory	laboratory	NOUN
bjp-38807	48	3	tests	test	NOUN
bjp-38807	48	4	were	be	AUX
bjp-38807	48	5	performed	perform	VERB
bjp-38807	48	6	at	at	ADP
bjp-38807	48	7	each	each	DET
bjp-38807	48	8	visit	visit	NOUN
bjp-38807	48	9	.	.	PUNCT
bjp-38807	49	1	statistical	statistical	ADJ
bjp-38807	49	2	analysis	analysis	NOUN
bjp-38807	49	3	since	since	SCONJ
bjp-38807	49	4	,	,	PUNCT
bjp-38807	49	5	the	the	DET
bjp-38807	49	6	present	present	ADJ
bjp-38807	49	7	study	study	NOUN
bjp-38807	49	8	designed	design	VERB
bjp-38807	49	9	as	as	ADP
bjp-38807	49	10	a	a	DET
bjp-38807	49	11	preliminary	preliminary	ADJ
bjp-38807	49	12	or	or	CCONJ
bjp-38807	49	13	pilot	pilot	NOUN
bjp-38807	49	14	study	study	NOUN
bjp-38807	49	15	,	,	PUNCT
bjp-38807	49	16	thus	thus	ADV
bjp-38807	49	17	,	,	PUNCT
bjp-38807	49	18	no	no	DET
bjp-38807	49	19	official	official	ADJ
bjp-38807	49	20	sample	sample	NOUN
bjp-38807	49	21	size	size	NOUN
bjp-38807	49	22	calculation	calculation	NOUN
bjp-38807	49	23	was	be	AUX
bjp-38807	49	24	performed	perform	VERB
bjp-38807	49	25	.	.	PUNCT
bjp-38807	50	1	to	to	PART
bjp-38807	50	2	assess	assess	VERB
bjp-38807	50	3	the	the	DET
bjp-38807	50	4	efficacy	efficacy	NOUN
bjp-38807	50	5	of	of	ADP
bjp-38807	50	6	treatment	treatment	NOUN
bjp-38807	50	7	,	,	PUNCT
bjp-38807	50	8	progression	progression	NOUN
bjp-38807	50	9	-	-	PUNCT
bjp-38807	50	10	free	free	ADJ
bjp-38807	50	11	survival	survival	NOUN
bjp-38807	50	12	and	and	CCONJ
bjp-38807	50	13	overall	overall	ADJ
bjp-38807	50	14	survival	survival	NOUN
bjp-38807	50	15	were	be	AUX
bjp-38807	50	16	compared	compare	VERB
bjp-38807	50	17	between	between	ADP
bjp-38807	50	18	both	both	CCONJ
bjp-38807	50	19	the	the	DET
bjp-38807	50	20	treatment	treatment	NOUN
bjp-38807	50	21	groups	group	NOUN
bjp-38807	50	22	using	use	VERB
bjp-38807	50	23	a	a	DET
bjp-38807	50	24	log	log	NOUN
bjp-38807	50	25	-	-	PUNCT
bjp-38807	50	26	rank	rank	NOUN
bjp-38807	50	27	test	test	NOUN
bjp-38807	50	28	,	,	PUNCT
bjp-38807	50	29	and	and	CCONJ
bjp-38807	50	30	hazard	hazard	NOUN
bjp-38807	50	31	ratio	ratio	NOUN
bjp-38807	50	32	(	(	PUNCT
bjp-38807	50	33	with	with	ADP
bjp-38807	50	34	95	95	NUM
bjp-38807	50	35	%	%	NOUN
bjp-38807	50	36	confidence	confidence	NOUN
bjp-38807	50	37	interval	interval	NOUN
bjp-38807	50	38	)	)	PUNCT
bjp-38807	50	39	was	be	AUX
bjp-38807	50	40	calculated	calculate	VERB
bjp-38807	50	41	.	.	PUNCT
bjp-38807	51	1	safety	safety	NOUN
bjp-38807	51	2	data	datum	NOUN
bjp-38807	51	3	were	be	AUX
bjp-38807	51	4	summarized	summarize	VERB
bjp-38807	51	5	by	by	ADP
bjp-38807	51	6	treatment	treatment	NOUN
bjp-38807	51	7	group	group	NOUN
bjp-38807	51	8	and	and	CCONJ
bjp-38807	51	9	presented	present	VERB
bjp-38807	51	10	descriptively	descriptively	ADV
bjp-38807	51	11	.	.	PUNCT
bjp-38807	52	1	results	result	VERB
bjp-38807	52	2	patient	patient	ADJ
bjp-38807	52	3	characteristics	characteristic	NOUN
bjp-38807	52	4	ad	ad	NOUN
bjp-38807	52	5	dose	dose	NOUN
bjp-38807	52	6	exposure	exposure	NOUN
bjp-38807	52	7	the	the	DET
bjp-38807	52	8	majority	majority	NOUN
bjp-38807	52	9	of	of	ADP
bjp-38807	52	10	patients	patient	NOUN
bjp-38807	52	11	in	in	ADP
bjp-38807	52	12	both	both	DET
bjp-38807	52	13	groups	group	NOUN
bjp-38807	52	14	had	have	VERB
bjp-38807	52	15	karnofsky	karnofsky	ADJ
bjp-38807	52	16	performance	performance	NOUN
bjp-38807	52	17	status	status	NOUN
bjp-38807	52	18	of	of	ADP
bjp-38807	52	19	less	less	ADJ
bjp-38807	52	20	than	than	ADP
bjp-38807	52	21	50	50	NUM
bjp-38807	52	22	%	%	NOUN
bjp-38807	52	23	.	.	PUNCT
bjp-38807	53	1	in	in	ADP
bjp-38807	53	2	general	general	ADJ
bjp-38807	53	3	,	,	PUNCT
bjp-38807	53	4	both	both	DET
bjp-38807	53	5	groups	group	NOUN
bjp-38807	53	6	were	be	AUX
bjp-38807	53	7	similar	similar	ADJ
bjp-38807	53	8	in	in	ADP
bjp-38807	53	9	terms	term	NOUN
bjp-38807	53	10	of	of	ADP
bjp-38807	53	11	baseline	baseline	ADJ
bjp-38807	53	12	demography	demography	NOUN
bjp-38807	53	13	and	and	CCONJ
bjp-38807	53	14	disease	disease	NOUN
bjp-38807	53	15	characteristics	characteristic	NOUN
bjp-38807	53	16	(	(	PUNCT
bjp-38807	53	17	table	table	NOUN
bjp-38807	53	18	i	i	NOUN
bjp-38807	53	19	)	)	PUNCT
bjp-38807	53	20	.	.	PUNCT
bjp-38807	54	1	the	the	DET
bjp-38807	54	2	patients	patient	NOUN
bjp-38807	54	3	in	in	ADP
bjp-38807	54	4	the	the	DET
bjp-38807	54	5	regorafenib	regorafenib	PROPN
bjp-38807	54	6	group	group	NOUN
bjp-38807	54	7	were	be	AUX
bjp-38807	54	8	treated	treat	VERB
bjp-38807	54	9	for	for	ADP
bjp-38807	54	10	a	a	DET
bjp-38807	54	11	longer	long	ADJ
bjp-38807	54	12	period	period	NOUN
bjp-38807	54	13	than	than	ADP
bjp-38807	54	14	those	those	PRON
bjp-38807	54	15	in	in	ADP
bjp-38807	54	16	the	the	DET
bjp-38807	54	17	dinutuximab	dinutuximab	NOUN
bjp-38807	54	18	with	with	ADP
bjp-38807	54	19	chemotherapy	chemotherapy	NOUN
bjp-38807	54	20	group	group	NOUN
bjp-38807	54	21	,	,	PUNCT
bjp-38807	54	22	with	with	ADP
bjp-38807	54	23	a	a	DET
bjp-38807	54	24	mean	mean	ADJ
bjp-38807	54	25	treatment	treatment	NOUN
bjp-38807	54	26	duration	duration	NOUN
bjp-38807	54	27	of	of	ADP
bjp-38807	54	28	3.2	3.2	NUM
bjp-38807	54	29	months	month	NOUN
bjp-38807	54	30	versus	versus	ADP
bjp-38807	54	31	2.2	2.2	NUM
bjp-38807	54	32	months	month	NOUN
bjp-38807	54	33	,	,	PUNCT
bjp-38807	54	34	respectively	respectively	ADV
bjp-38807	54	35	.	.	PUNCT
bjp-38807	55	1	the	the	DET
bjp-38807	55	2	patients	patient	NOUN
bjp-38807	55	3	in	in	ADP
bjp-38807	55	4	the	the	DET
bjp-38807	55	5	regorafenib	regorafenib	PROPN
bjp-38807	55	6	group	group	NOUN
bjp-38807	55	7	received	receive	VERB
bjp-38807	55	8	more	more	ADJ
bjp-38807	55	9	treatment	treatment	NOUN
bjp-38807	55	10	cycles	cycle	NOUN
bjp-38807	55	11	than	than	ADP
bjp-38807	55	12	those	those	PRON
bjp-38807	55	13	in	in	ADP
bjp-38807	55	14	the	the	DET
bjp-38807	55	15	dinutuximab	dinutuximab	NOUN
bjp-38807	55	16	with	with	ADP
bjp-38807	55	17	chemotherapy	chemotherapy	NOUN
bjp-38807	55	18	group	group	NOUN
bjp-38807	55	19	,	,	PUNCT
bjp-38807	55	20	with	with	ADP
bjp-38807	55	21	a	a	DET
bjp-38807	55	22	mean	mean	ADJ
bjp-38807	55	23	(	(	PUNCT
bjp-38807	55	24	sd	sd	NOUN
bjp-38807	55	25	)	)	PUNCT
bjp-38807	55	26	treatment	treatment	NOUN
bjp-38807	55	27	cycle	cycle	NOUN
bjp-38807	55	28	of	of	ADP
bjp-38807	55	29	6.1	6.1	NUM
bjp-38807	55	30	(	(	PUNCT
bjp-38807	55	31	1.18	1.18	NUM
bjp-38807	55	32	)	)	PUNCT
bjp-38807	55	33	versus	versus	ADP
bjp-38807	55	34	3.9	3.9	NUM
bjp-38807	55	35	(	(	PUNCT
bjp-38807	55	36	2.11	2.11	NUM
bjp-38807	55	37	)	)	PUNCT
bjp-38807	55	38	.	.	PUNCT
bjp-38807	56	1	efficacy	efficacy	NOUN
bjp-38807	56	2	the	the	DET
bjp-38807	56	3	patients	patient	NOUN
bjp-38807	56	4	who	who	PRON
bjp-38807	56	5	were	be	AUX
bjp-38807	56	6	treated	treat	VERB
bjp-38807	56	7	with	with	ADP
bjp-38807	56	8	regorafenib	regorafenib	NOUN
bjp-38807	56	9	showed	show	VERB
bjp-38807	56	10	prolonged	prolonged	ADJ
bjp-38807	56	11	overall	overall	ADJ
bjp-38807	56	12	survival	survival	NOUN
bjp-38807	56	13	compared	compare	VERB
bjp-38807	56	14	to	to	ADP
bjp-38807	56	15	those	those	PRON
bjp-38807	56	16	who	who	PRON
bjp-38807	56	17	received	receive	VERB
bjp-38807	56	18	dinutuximab	dinutuximab	NOUN
bjp-38807	56	19	plus	plus	CCONJ
bjp-38807	56	20	chemotherapy	chemotherapy	NOUN
bjp-38807	56	21	(	(	PUNCT
bjp-38807	56	22	median	median	NOUN
bjp-38807	56	23	32.30	32.30	NUM
bjp-38807	56	24	months	month	NOUN
bjp-38807	56	25	versus	versus	ADP
bjp-38807	56	26	27.17	27.17	NUM
bjp-38807	56	27	months	month	NOUN
bjp-38807	56	28	;	;	PUNCT
bjp-38807	56	29	hazard	hazard	NOUN
bjp-38807	56	30	ratio	ratio	NOUN
bjp-38807	56	31	=	=	NOUN
bjp-38807	56	32	0.45	0.45	NUM
bjp-38807	56	33	;	;	PUNCT
bjp-38807	56	34	95	95	NUM
bjp-38807	56	35	%	%	NOUN
bjp-38807	56	36	ci	ci	NOUN
bjp-38807	56	37	0.11	0.11	NUM
bjp-38807	56	38	-	-	SYM
bjp-38807	56	39	0.13	0.13	NUM
bjp-38807	56	40	,	,	PUNCT
bjp-38807	56	41	p<0.001	p<0.001	PROPN
bjp-38807	56	42	)	)	PUNCT
bjp-38807	56	43	.	.	PUNCT
bjp-38807	57	1	also	also	ADV
bjp-38807	57	2	,	,	PUNCT
bjp-38807	57	3	progression	progression	NOUN
bjp-38807	57	4	-	-	PUNCT
bjp-38807	57	5	free	free	ADJ
bjp-38807	57	6	survival	survival	NOUN
bjp-38807	57	7	was	be	AUX
bjp-38807	57	8	significantly	significantly	ADV
bjp-38807	57	9	prolonged	prolong	VERB
bjp-38807	57	10	for	for	ADP
bjp-38807	57	11	the	the	DET
bjp-38807	57	12	patients	patient	NOUN
bjp-38807	57	13	who	who	PRON
bjp-38807	57	14	were	be	AUX
bjp-38807	57	15	treated	treat	VERB
bjp-38807	57	16	with	with	ADP
bjp-38807	57	17	regorafenib	regorafenib	NOUN
bjp-38807	57	18	compared	compare	VERB
bjp-38807	57	19	with	with	ADP
bjp-38807	57	20	patients	patient	NOUN
bjp-38807	57	21	who	who	PRON
bjp-38807	57	22	received	receive	VERB
bjp-38807	57	23	dinutuximab	dinutuximab	NOUN
bjp-38807	57	24	with	with	ADP
bjp-38807	57	25	chemotherapy	chemotherapy	NOUN
bjp-38807	57	26	(	(	PUNCT
bjp-38807	57	27	stratified	stratify	VERB
bjp-38807	57	28	hazard	hazard	NOUN
bjp-38807	57	29	ratio	ratio	NOUN
bjp-38807	57	30	=	=	PROPN
bjp-38807	57	31	0.48	0.48	NUM
bjp-38807	57	32	;	;	PUNCT
bjp-38807	57	33	95	95	NUM
bjp-38807	57	34	%	%	NOUN
bjp-38807	57	35	ci	ci	NOUN
bjp-38807	57	36	0.11	0.11	NUM
bjp-38807	57	37	-	-	SYM
bjp-38807	57	38	0.14	0.14	NUM
bjp-38807	57	39	;	;	PUNCT
bjp-38807	57	40	bangladesh	bangladesh	PROPN
bjp-38807	57	41	j	j	PROPN
bjp-38807	57	42	pharmacol	pharmacol	PROPN
bjp-38807	57	43	2019	2019	NUM
bjp-38807	57	44	;	;	PUNCT
bjp-38807	57	45	14	14	NUM
bjp-38807	57	46	:	:	SYM
bjp-38807	57	47	32	32	NUM
bjp-38807	57	48	-	-	SYM
bjp-38807	57	49	35	35	NUM
bjp-38807	57	50	33	33	NUM
bjp-38807	57	51	p<0.001	p<0.001	NOUN
bjp-38807	57	52	)	)	PUNCT
bjp-38807	57	53	.	.	PUNCT
bjp-38807	58	1	moreover	moreover	ADV
bjp-38807	58	2	,	,	PUNCT
bjp-38807	58	3	the	the	DET
bjp-38807	58	4	overall	overall	ADJ
bjp-38807	58	5	response	response	NOUN
bjp-38807	58	6	rate	rate	NOUN
bjp-38807	58	7	was	be	AUX
bjp-38807	58	8	greater	great	ADJ
bjp-38807	58	9	in	in	ADP
bjp-38807	58	10	patients	patient	NOUN
bjp-38807	58	11	treated	treat	VERB
bjp-38807	58	12	with	with	ADP
bjp-38807	58	13	regorafenib	regorafenib	NOUN
bjp-38807	58	14	as	as	SCONJ
bjp-38807	58	15	compared	compare	VERB
bjp-38807	58	16	to	to	PART
bjp-38807	58	17	dinutuximab	dinutuximab	VERB
bjp-38807	58	18	with	with	ADP
bjp-38807	58	19	chemotherapy	chemotherapy	NOUN
bjp-38807	58	20	(	(	PUNCT
bjp-38807	58	21	table	table	NOUN
bjp-38807	58	22	ii	ii	PROPN
bjp-38807	58	23	)	)	PUNCT
bjp-38807	58	24	.	.	PUNCT
bjp-38807	59	1	safety	safety	NOUN
bjp-38807	59	2	and	and	CCONJ
bjp-38807	59	3	tolerability	tolerability	NOUN
bjp-38807	59	4	in	in	ADP
bjp-38807	59	5	regorafenib	regorafenib	NOUN
bjp-38807	59	6	group	group	NOUN
bjp-38807	59	7	,	,	PUNCT
bjp-38807	59	8	the	the	DET
bjp-38807	59	9	most	most	ADV
bjp-38807	59	10	common	common	ADJ
bjp-38807	59	11	treatmentrelated	treatmentrelated	ADJ
bjp-38807	59	12	adverse	adverse	ADJ
bjp-38807	59	13	events	event	NOUN
bjp-38807	59	14	of	of	ADP
bjp-38807	59	15	all	all	DET
bjp-38807	59	16	grades	grade	NOUN
bjp-38807	59	17	were	be	AUX
bjp-38807	59	18	hypertension	hypertension	NOUN
bjp-38807	59	19	,	,	PUNCT
bjp-38807	59	20	palmar	palmar	X
bjp-38807	59	21	-	-	PUNCT
bjp-38807	59	22	plantar	plantar	ADJ
bjp-38807	59	23	erythrodysaesthesia	erythrodysaesthesia	PROPN
bjp-38807	59	24	syndrome	syndrome	NOUN
bjp-38807	59	25	handfoot	handfoot	NOUN
bjp-38807	59	26	-	-	PUNCT
bjp-38807	59	27	skin	skin	NOUN
bjp-38807	59	28	-	-	PUNCT
bjp-38807	59	29	reaction	reaction	NOUN
bjp-38807	59	30	,	,	PUNCT
bjp-38807	59	31	and	and	CCONJ
bjp-38807	59	32	proteinuria	proteinuria	NOUN
bjp-38807	59	33	(	(	PUNCT
bjp-38807	59	34	table	table	NOUN
bjp-38807	59	35	iii	iii	NOUN
bjp-38807	59	36	)	)	PUNCT
bjp-38807	59	37	.	.	PUNCT
bjp-38807	60	1	the	the	DET
bjp-38807	60	2	most	most	ADV
bjp-38807	60	3	common	common	ADJ
bjp-38807	60	4	treatment	treatment	NOUN
bjp-38807	60	5	-	-	PUNCT
bjp-38807	60	6	related	relate	VERB
bjp-38807	60	7	grade	grade	NOUN
bjp-38807	60	8	≥3	≥3	PROPN
bjp-38807	60	9	aesis	aesis	NOUN
bjp-38807	60	10	were	be	AUX
bjp-38807	60	11	hypertension	hypertension	NOUN
bjp-38807	60	12	,	,	PUNCT
bjp-38807	60	13	hand	hand	NOUN
bjp-38807	60	14	-	-	PUNCT
bjp-38807	60	15	foot	foot	NOUN
bjp-38807	60	16	-	-	PUNCT
bjp-38807	60	17	skin	skin	NOUN
bjp-38807	60	18	-	-	PUNCT
bjp-38807	60	19	reaction	reaction	NOUN
bjp-38807	60	20	,	,	PUNCT
bjp-38807	60	21	and	and	CCONJ
bjp-38807	60	22	proteinuria	proteinuria	NOUN
bjp-38807	60	23	.	.	PUNCT
bjp-38807	61	1	discussion	discussion	NOUN
bjp-38807	61	2	the	the	DET
bjp-38807	61	3	overall	overall	ADJ
bjp-38807	61	4	efficacy	efficacy	NOUN
bjp-38807	61	5	and	and	CCONJ
bjp-38807	61	6	safety	safety	NOUN
bjp-38807	61	7	profile	profile	NOUN
bjp-38807	61	8	of	of	ADP
bjp-38807	61	9	regorafenib	regorafenib	NOUN
bjp-38807	61	10	in	in	ADP
bjp-38807	61	11	this	this	DET
bjp-38807	61	12	study	study	NOUN
bjp-38807	61	13	was	be	AUX
bjp-38807	61	14	consistent	consistent	ADJ
bjp-38807	61	15	with	with	ADP
bjp-38807	61	16	the	the	DET
bjp-38807	61	17	known	know	VERB
bjp-38807	61	18	efficacy	efficacy	NOUN
bjp-38807	61	19	and	and	CCONJ
bjp-38807	61	20	safety	safety	NOUN
bjp-38807	61	21	profile	profile	NOUN
bjp-38807	61	22	of	of	ADP
bjp-38807	61	23	regorafenib	regorafenib	NOUN
bjp-38807	61	24	in	in	ADP
bjp-38807	61	25	other	other	ADJ
bjp-38807	61	26	cancer	cancer	NOUN
bjp-38807	61	27	treatment	treatment	NOUN
bjp-38807	61	28	.	.	PUNCT
bjp-38807	62	1	moreover	moreover	ADV
bjp-38807	62	2	,	,	PUNCT
bjp-38807	62	3	the	the	DET
bjp-38807	62	4	safety	safety	NOUN
bjp-38807	62	5	and	and	CCONJ
bjp-38807	62	6	efficacy	efficacy	NOUN
bjp-38807	62	7	profile	profile	NOUN
bjp-38807	62	8	of	of	ADP
bjp-38807	62	9	regorafenib	regorafenib	NOUN
bjp-38807	62	10	was	be	AUX
bjp-38807	62	11	mostly	mostly	ADV
bjp-38807	62	12	similar	similar	ADJ
bjp-38807	62	13	with	with	ADP
bjp-38807	62	14	those	those	PRON
bjp-38807	62	15	of	of	ADP
bjp-38807	62	16	other	other	ADJ
bjp-38807	62	17	small	small	ADJ
bjp-38807	62	18	molecular	molecular	ADJ
bjp-38807	62	19	multi	multi	ADJ
bjp-38807	62	20	-	-	ADJ
bjp-38807	62	21	target	target	ADJ
bjp-38807	62	22	inhibitors	inhibitor	NOUN
bjp-38807	62	23	which	which	PRON
bjp-38807	62	24	also	also	ADV
bjp-38807	62	25	antagonizing	antagonize	VERB
bjp-38807	62	26	vegfr	vegfr	NOUN
bjp-38807	62	27	(	(	PUNCT
bjp-38807	62	28	motzer	motzer	NOUN
bjp-38807	62	29	et	et	PROPN
bjp-38807	62	30	al	al	PROPN
bjp-38807	62	31	.	.	PROPN
bjp-38807	62	32	,	,	PUNCT
bjp-38807	62	33	2007	2007	NUM
bjp-38807	62	34	;	;	PUNCT
bjp-38807	62	35	escudier	escudi	ADJ
bjp-38807	62	36	et	et	PROPN
bjp-38807	62	37	al	al	PROPN
bjp-38807	62	38	.	.	PROPN
bjp-38807	62	39	,	,	PUNCT
bjp-38807	62	40	2007	2007	NUM
bjp-38807	62	41	;	;	PUNCT
bjp-38807	62	42	motzer	motzer	NOUN
bjp-38807	62	43	et	et	PROPN
bjp-38807	62	44	al	al	PROPN
bjp-38807	62	45	.	.	PROPN
bjp-38807	62	46	,	,	PUNCT
bjp-38807	62	47	2013	2013	NUM
bjp-38807	62	48	;	;	PUNCT
bjp-38807	62	49	motzer	motzer	NOUN
bjp-38807	62	50	et	et	PROPN
bjp-38807	62	51	al	al	PROPN
bjp-38807	62	52	.	.	PROPN
bjp-38807	62	53	,	,	PUNCT
bjp-38807	62	54	2009	2009	NUM
bjp-38807	62	55	;	;	PUNCT
bjp-38807	62	56	escudier	escudi	ADJ
bjp-38807	62	57	et	et	PROPN
bjp-38807	62	58	al	al	PROPN
bjp-38807	62	59	.	.	PROPN
bjp-38807	62	60	,	,	PUNCT
bjp-38807	62	61	2007	2007	NUM
bjp-38807	62	62	;	;	PUNCT
bjp-38807	62	63	kamba	kamba	NOUN
bjp-38807	62	64	and	and	CCONJ
bjp-38807	62	65	mcdonald	mcdonald	PROPN
bjp-38807	62	66	,	,	PUNCT
bjp-38807	62	67	2007	2007	NUM
bjp-38807	62	68	;	;	PUNCT
bjp-38807	62	69	lacouture	lacouture	NOUN
bjp-38807	62	70	et	et	PROPN
bjp-38807	62	71	al	al	PROPN
bjp-38807	62	72	.	.	PROPN
bjp-38807	62	73	,	,	PUNCT
bjp-38807	62	74	2008	2008	NUM
bjp-38807	62	75	)	)	PUNCT
bjp-38807	62	76	.	.	PUNCT
bjp-38807	63	1	in	in	ADP
bjp-38807	63	2	general	general	ADJ
bjp-38807	63	3	,	,	PUNCT
bjp-38807	63	4	regorafenib	regorafenib	NOUN
bjp-38807	63	5	treatment	treatment	NOUN
bjp-38807	63	6	was	be	AUX
bjp-38807	63	7	well	well	ADV
bjp-38807	63	8	-	-	PUNCT
bjp-38807	63	9	tolerated	tolerate	VERB
bjp-38807	63	10	in	in	ADP
bjp-38807	63	11	chinese	chinese	ADJ
bjp-38807	63	12	children	child	NOUN
bjp-38807	63	13	with	with	ADP
bjp-38807	63	14	advanced	advanced	ADJ
bjp-38807	63	15	neuroblastoma	neuroblastoma	NOUN
bjp-38807	63	16	.	.	PUNCT
bjp-38807	64	1	in	in	ADP
bjp-38807	64	2	the	the	DET
bjp-38807	64	3	study	study	NOUN
bjp-38807	64	4	,	,	PUNCT
bjp-38807	64	5	the	the	DET
bjp-38807	64	6	most	most	ADV
bjp-38807	64	7	common	common	ADJ
bjp-38807	64	8	treatment	treatment	NOUN
bjp-38807	64	9	-	-	PUNCT
bjp-38807	64	10	related	relate	VERB
bjp-38807	64	11	adverse	adverse	ADJ
bjp-38807	64	12	event	event	NOUN
bjp-38807	64	13	occurred	occur	VERB
bjp-38807	64	14	in	in	ADP
bjp-38807	64	15	neuroblastoma	neuroblastoma	ADJ
bjp-38807	64	16	patients	patient	NOUN
bjp-38807	64	17	treated	treat	VERB
bjp-38807	64	18	with	with	ADP
bjp-38807	64	19	regorafenib	regorafenib	NOUN
bjp-38807	64	20	were	be	AUX
bjp-38807	64	21	hypertension	hypertension	NOUN
bjp-38807	64	22	,	,	PUNCT
bjp-38807	64	23	hand	hand	NOUN
bjp-38807	64	24	-	-	PUNCT
bjp-38807	64	25	foot	foot	NOUN
bjp-38807	64	26	-	-	PUNCT
bjp-38807	64	27	skin	skin	NOUN
bjp-38807	64	28	-	-	PUNCT
bjp-38807	64	29	reaction	reaction	NOUN
bjp-38807	64	30	,	,	PUNCT
bjp-38807	64	31	proteinuria	proteinuria	NOUN
bjp-38807	64	32	,	,	PUNCT
bjp-38807	64	33	and	and	CCONJ
bjp-38807	64	34	hemorrhage	hemorrhage	NOUN
bjp-38807	64	35	.	.	PUNCT
bjp-38807	65	1	the	the	DET
bjp-38807	65	2	most	most	ADV
bjp-38807	65	3	common	common	ADJ
bjp-38807	65	4	treatment	treatment	NOUN
bjp-38807	65	5	-	-	PUNCT
bjp-38807	65	6	related	relate	VERB
bjp-38807	65	7	grade	grade	NOUN
bjp-38807	65	8	≥3	≥3	PROPN
bjp-38807	65	9	adverse	adverse	ADJ
bjp-38807	65	10	events	event	NOUN
bjp-38807	65	11	were	be	AUX
bjp-38807	65	12	hypertension	hypertension	NOUN
bjp-38807	65	13	,	,	PUNCT
bjp-38807	65	14	hand	hand	NOUN
bjp-38807	65	15	-	-	PUNCT
bjp-38807	65	16	foot	foot	NOUN
bjp-38807	65	17	-	-	PUNCT
bjp-38807	65	18	skin	skin	NOUN
bjp-38807	65	19	-	-	PUNCT
bjp-38807	65	20	reaction	reaction	NOUN
bjp-38807	65	21	,	,	PUNCT
bjp-38807	65	22	and	and	CCONJ
bjp-38807	65	23	proteinuria	proteinuria	NOUN
bjp-38807	65	24	.	.	PUNCT
bjp-38807	66	1	hypertension	hypertension	NOUN
bjp-38807	66	2	was	be	AUX
bjp-38807	66	3	the	the	DET
bjp-38807	66	4	most	most	ADV
bjp-38807	66	5	commonly	commonly	ADV
bjp-38807	66	6	reported	report	VERB
bjp-38807	66	7	treatmentrelated	treatmentrelate	VERB
bjp-38807	66	8	adverse	adverse	ADJ
bjp-38807	66	9	event	event	NOUN
bjp-38807	66	10	which	which	PRON
bjp-38807	66	11	is	be	AUX
bjp-38807	66	12	expected	expect	VERB
bjp-38807	66	13	safety	safety	NOUN
bjp-38807	66	14	concern	concern	NOUN
bjp-38807	66	15	with	with	ADP
bjp-38807	66	16	various	various	ADJ
bjp-38807	66	17	anti	anti	ADJ
bjp-38807	66	18	-	-	ADJ
bjp-38807	66	19	vegf	vegf	ADJ
bjp-38807	66	20	/	/	SYM
bjp-38807	66	21	vegfr	vegfr	NOUN
bjp-38807	66	22	agents	agent	NOUN
bjp-38807	66	23	(	(	PUNCT
bjp-38807	66	24	motzer	motzer	NOUN
bjp-38807	66	25	et	et	PROPN
bjp-38807	66	26	al	al	PROPN
bjp-38807	66	27	.	.	PROPN
bjp-38807	66	28	,	,	PUNCT
bjp-38807	66	29	2013	2013	NUM
bjp-38807	66	30	;	;	PUNCT
bjp-38807	66	31	motzer	motzer	NOUN
bjp-38807	66	32	et	et	PROPN
bjp-38807	66	33	al	al	PROPN
bjp-38807	66	34	.	.	PROPN
bjp-38807	66	35	,	,	PUNCT
bjp-38807	66	36	2009	2009	NUM
bjp-38807	66	37	;	;	PUNCT
bjp-38807	66	38	escudier	escudi	ADJ
bjp-38807	66	39	et	et	PROPN
bjp-38807	66	40	al	al	PROPN
bjp-38807	66	41	.	.	PROPN
bjp-38807	66	42	,	,	PUNCT
bjp-38807	66	43	2007	2007	NUM
bjp-38807	66	44	;	;	PUNCT
bjp-38807	66	45	kamba	kamba	NOUN
bjp-38807	66	46	and	and	CCONJ
bjp-38807	66	47	mcdonald	mcdonald	PROPN
bjp-38807	66	48	,	,	PUNCT
bjp-38807	66	49	2007	2007	NUM
bjp-38807	66	50	;	;	PUNCT
bjp-38807	66	51	lacouture	lacouture	NOUN
bjp-38807	66	52	et	et	PROPN
bjp-38807	66	53	al	al	PROPN
bjp-38807	66	54	.	.	PROPN
bjp-38807	66	55	,	,	PUNCT
bjp-38807	66	56	2008	2008	NUM
bjp-38807	66	57	)	)	PUNCT
bjp-38807	66	58	.	.	PUNCT
bjp-38807	67	1	this	this	PRON
bjp-38807	67	2	was	be	AUX
bjp-38807	67	3	table	table	NOUN
bjp-38807	67	4	i	i	PRON
bjp-38807	67	5	characteristics	characteristic	NOUN
bjp-38807	67	6	of	of	ADP
bjp-38807	67	7	the	the	DET
bjp-38807	67	8	patients	patient	NOUN
bjp-38807	67	9	best	well	ADV
bjp-38807	67	10	supportive	supportive	ADJ
bjp-38807	67	11	care	care	NOUN
bjp-38807	67	12	plus	plus	CCONJ
bjp-38807	67	13	characteristics	characteristic	NOUN
bjp-38807	67	14	regorafenib	regorafenib	PROPN
bjp-38807	67	15	dinutuximab	dinutuximab	NOUN
bjp-38807	67	16	plus	plus	CCONJ
bjp-38807	67	17	chemotherapy	chemotherapy	NOUN
bjp-38807	67	18	age	age	NOUN
bjp-38807	67	19	<	<	X
bjp-38807	67	20	10	10	NUM
bjp-38807	67	21	years	year	NOUN
bjp-38807	67	22	(	(	PUNCT
bjp-38807	67	23	n	n	CCONJ
bjp-38807	67	24	)	)	PUNCT
bjp-38807	67	25	16	16	NUM
bjp-38807	67	26	13	13	NUM
bjp-38807	67	27	≥10	≥10	NUM
bjp-38807	67	28	years	year	NOUN
bjp-38807	67	29	(	(	PUNCT
bjp-38807	67	30	n	n	CCONJ
bjp-38807	67	31	)	)	PUNCT
bjp-38807	67	32	14	14	NUM
bjp-38807	67	33	17	17	NUM
bjp-38807	67	34	gender	gender	NOUN
bjp-38807	67	35	male	male	NOUN
bjp-38807	67	36	(	(	PUNCT
bjp-38807	67	37	n	n	CCONJ
bjp-38807	67	38	)	)	PUNCT
bjp-38807	67	39	20	20	NUM
bjp-38807	67	40	11	11	NUM
bjp-38807	67	41	female	female	NOUN
bjp-38807	67	42	(	(	PUNCT
bjp-38807	67	43	n	n	CCONJ
bjp-38807	67	44	)	)	PUNCT
bjp-38807	67	45	10	10	NUM
bjp-38807	67	46	19	19	NUM
bjp-38807	67	47	ethnicity	ethnicity	NOUN
bjp-38807	67	48	han	han	NOUN
bjp-38807	67	49	(	(	PUNCT
bjp-38807	67	50	chinese	chinese	PROPN
bjp-38807	67	51	)	)	PUNCT
bjp-38807	67	52	28	28	NUM
bjp-38807	67	53	27	27	NUM
bjp-38807	67	54	not	not	PART
bjp-38807	67	55	han	han	PROPN
bjp-38807	67	56	(	(	PUNCT
bjp-38807	67	57	chinese	chinese	PROPN
bjp-38807	67	58	)	)	PUNCT
bjp-38807	68	1	2	2	NUM
bjp-38807	68	2	3	3	NUM
bjp-38807	68	3	karnofsky	karnofsky	ADJ
bjp-38807	68	4	performance	performance	NOUN
bjp-38807	68	5	status	status	NOUN
bjp-38807	68	6	≤50	≤50	PROPN
bjp-38807	69	1	%	%	NOUN
bjp-38807	69	2	26	26	NUM
bjp-38807	69	3	25	25	NUM
bjp-38807	69	4	>	>	SYM
bjp-38807	69	5	50	50	NUM
bjp-38807	69	6	%	%	NOUN
bjp-38807	69	7	4	4	NUM
bjp-38807	69	8	5	5	NUM
bjp-38807	69	9	site	site	NOUN
bjp-38807	69	10	of	of	ADP
bjp-38807	69	11	tumor	tumor	NOUN
bjp-38807	69	12	primary	primary	ADJ
bjp-38807	69	13	22	22	NUM
bjp-38807	69	14	19	19	NUM
bjp-38807	69	15	metastatic	metastatic	ADJ
bjp-38807	69	16	8	8	NUM
bjp-38807	69	17	11	11	NUM
bjp-38807	69	18	mutations	mutation	NOUN
bjp-38807	69	19	in	in	ADP
bjp-38807	69	20	the	the	DET
bjp-38807	69	21	kirsten	kirsten	PROPN
bjp-38807	69	22	ras	ras	PROPN
bjp-38807	69	23	gene	gene	NOUN
bjp-38807	69	24	status	status	NOUN
bjp-38807	69	25	wild	wild	ADJ
bjp-38807	69	26	type	type	NOUN
bjp-38807	69	27	29	29	NUM
bjp-38807	69	28	28	28	NUM
bjp-38807	69	29	mutant	mutant	NOUN
bjp-38807	69	30	1	1	NUM
bjp-38807	69	31	2	2	NUM
bjp-38807	69	32	prior	prior	ADJ
bjp-38807	69	33	use	use	NOUN
bjp-38807	69	34	of	of	ADP
bjp-38807	69	35	anti	anti	ADJ
bjp-38807	69	36	-	-	ADJ
bjp-38807	69	37	vegf	vegf	ADJ
bjp-38807	69	38	treatment	treatment	NOUN
bjp-38807	69	39	16	16	NUM
bjp-38807	69	40	18	18	NUM
bjp-38807	69	41	prior	prior	ADJ
bjp-38807	69	42	use	use	NOUN
bjp-38807	69	43	of	of	ADP
bjp-38807	69	44	anti	anti	ADJ
bjp-38807	69	45	-	-	ADJ
bjp-38807	69	46	egfr	egfr	ADJ
bjp-38807	69	47	treatment	treatment	NOUN
bjp-38807	69	48	15	15	NUM
bjp-38807	69	49	13	13	NUM
bjp-38807	69	50	liver	liver	NOUN
bjp-38807	69	51	metastasis	metastasis	NOUN
bjp-38807	69	52	0	0	NUM
bjp-38807	69	53	0	0	NUM
bjp-38807	70	1	n=30	n=30	NOUN
bjp-38807	70	2	in	in	ADP
bjp-38807	70	3	each	each	DET
bjp-38807	70	4	group	group	NOUN
bjp-38807	70	5	;	;	PUNCT
bjp-38807	70	6	abbreviations	abbreviation	NOUN
bjp-38807	70	7	:	:	PUNCT
bjp-38807	70	8	egfr=	egfr=	NUM
bjp-38807	70	9	epidermal	epidermal	ADJ
bjp-38807	70	10	growth	growth	NOUN
bjp-38807	70	11	factor	factor	NOUN
bjp-38807	70	12	receptor	receptor	NOUN
bjp-38807	70	13	;	;	PUNCT
bjp-38807	70	14	vegf=	vegf=	NUM
bjp-38807	70	15	vascular	vascular	ADJ
bjp-38807	70	16	endothelial	endothelial	ADJ
bjp-38807	70	17	growth	growth	NOUN
bjp-38807	70	18	factor	factor	NOUN
bjp-38807	70	19	table	table	NOUN
bjp-38807	70	20	ii	ii	PROPN
bjp-38807	70	21	efficacy	efficacy	PROPN
bjp-38807	70	22	comparison	comparison	NOUN
bjp-38807	70	23	of	of	ADP
bjp-38807	70	24	regorafenib	regorafenib	NOUN
bjp-38807	70	25	vs	vs	ADP
bjp-38807	70	26	dinutuximab	dinutuximab	NOUN
bjp-38807	70	27	plus	plus	CCONJ
bjp-38807	70	28	chemotherapy	chemotherapy	NOUN
bjp-38807	70	29	best	well	ADV
bjp-38807	70	30	supportive	supportive	ADJ
bjp-38807	70	31	care	care	NOUN
bjp-38807	70	32	plus	plus	CCONJ
bjp-38807	70	33	variables	variable	NOUN
bjp-38807	70	34	regorafenib	regorafenib	PROPN
bjp-38807	70	35	(	(	PUNCT
bjp-38807	70	36	n=30	n=30	NOUN
bjp-38807	70	37	)	)	PUNCT
bjp-38807	70	38	dinutuximab	dinutuximab	NOUN
bjp-38807	70	39	plus	plus	CCONJ
bjp-38807	70	40	chemotherapy	chemotherapy	NOUN
bjp-38807	70	41	(	(	PUNCT
bjp-38807	70	42	n=30	n=30	NOUN
bjp-38807	70	43	)	)	PUNCT
bjp-38807	70	44	overall	overall	ADJ
bjp-38807	70	45	survival	survival	NOUN
bjp-38807	70	46	median	median	PROPN
bjp-38807	70	47	in	in	ADP
bjp-38807	70	48	months	month	NOUN
bjp-38807	70	49	(	(	PUNCT
bjp-38807	70	50	95	95	NUM
bjp-38807	70	51	%	%	NOUN
bjp-38807	70	52	ci	ci	NOUN
bjp-38807	70	53	)	)	PUNCT
bjp-38807	70	54	32.3	32.3	NUM
bjp-38807	70	55	(	(	PUNCT
bjp-38807	70	56	8.1	8.1	NUM
bjp-38807	70	57	-	-	SYM
bjp-38807	70	58	10.5	10.5	NUM
bjp-38807	70	59	)	)	PUNCT
bjp-38807	70	60	27.2	27.2	NUM
bjp-38807	70	61	(	(	PUNCT
bjp-38807	70	62	5.7	5.7	NUM
bjp-38807	70	63	-	-	SYM
bjp-38807	70	64	8.1	8.1	NUM
bjp-38807	70	65	)	)	PUNCT
bjp-38807	70	66	stratified	stratify	VERB
bjp-38807	70	67	hazard	hazard	NOUN
bjp-38807	70	68	ratio	ratio	NOUN
bjp-38807	70	69	(	(	PUNCT
bjp-38807	70	70	95	95	NUM
bjp-38807	70	71	%	%	NOUN
bjp-38807	70	72	ci	ci	NOUN
bjp-38807	70	73	)	)	PUNCT
bjp-38807	70	74	,	,	PUNCT
bjp-38807	70	75	p	p	NOUN
bjp-38807	70	76	value	value	NOUN
bjp-38807	70	77	0.45	0.45	NUM
bjp-38807	70	78	(	(	PUNCT
bjp-38807	70	79	0.11	0.11	NUM
bjp-38807	70	80	-	-	SYM
bjp-38807	70	81	0.13	0.13	NUM
bjp-38807	70	82	)	)	PUNCT
bjp-38807	70	83	,	,	PUNCT
bjp-38807	70	84	p<0.001	p<0.001	VERB
bjp-38807	70	85	progression	progression	NOUN
bjp-38807	70	86	-	-	PUNCT
bjp-38807	70	87	free	free	ADJ
bjp-38807	70	88	survival	survival	NOUN
bjp-38807	70	89	median	median	NOUN
bjp-38807	70	90	in	in	ADP
bjp-38807	70	91	months	month	NOUN
bjp-38807	70	92	(	(	PUNCT
bjp-38807	70	93	95	95	NUM
bjp-38807	70	94	%	%	NOUN
bjp-38807	70	95	ci	ci	NOUN
bjp-38807	70	96	)	)	PUNCT
bjp-38807	70	97	8.8	8.8	NUM
bjp-38807	70	98	(	(	PUNCT
bjp-38807	70	99	4.7	4.7	NUM
bjp-38807	70	100	-	-	SYM
bjp-38807	70	101	10.6	10.6	NUM
bjp-38807	70	102	)	)	PUNCT
bjp-38807	70	103	5.1	5.1	NUM
bjp-38807	70	104	(	(	PUNCT
bjp-38807	70	105	2.8	2.8	NUM
bjp-38807	70	106	-	-	SYM
bjp-38807	70	107	8.8	8.8	NUM
bjp-38807	70	108	)	)	PUNCT
bjp-38807	70	109	stratified	stratify	VERB
bjp-38807	70	110	hazard	hazard	NOUN
bjp-38807	70	111	ratio	ratio	NOUN
bjp-38807	70	112	(	(	PUNCT
bjp-38807	70	113	95	95	NUM
bjp-38807	70	114	%	%	NOUN
bjp-38807	70	115	ci	ci	NOUN
bjp-38807	70	116	)	)	PUNCT
bjp-38807	70	117	,	,	PUNCT
bjp-38807	70	118	p	p	NOUN
bjp-38807	70	119	value	value	NOUN
bjp-38807	70	120	0.48	0.48	NUM
bjp-38807	70	121	(	(	PUNCT
bjp-38807	70	122	0.11	0.11	NUM
bjp-38807	70	123	-	-	SYM
bjp-38807	70	124	0.14	0.14	NUM
bjp-38807	70	125	)	)	PUNCT
bjp-38807	70	126	,	,	PUNCT
bjp-38807	71	1	p<0.001	p<0.001	VERB
bjp-38807	71	2	overall	overall	ADJ
bjp-38807	71	3	response	response	NOUN
bjp-38807	71	4	(	(	PUNCT
bjp-38807	71	5	n	n	CCONJ
bjp-38807	71	6	)	)	PUNCT
bjp-38807	71	7	complete	complete	ADJ
bjp-38807	71	8	response	response	NOUN
bjp-38807	71	9	2	2	NUM
bjp-38807	71	10	1	1	NUM
bjp-38807	71	11	partial	partial	ADJ
bjp-38807	71	12	response	response	NOUN
bjp-38807	71	13	13	13	NUM
bjp-38807	71	14	9	9	NUM
bjp-38807	71	15	stable	stable	ADJ
bjp-38807	71	16	disease	disease	NOUN
bjp-38807	71	17	12	12	NUM
bjp-38807	71	18	15	15	NUM
bjp-38807	71	19	progressive	progressive	ADJ
bjp-38807	71	20	disease	disease	NOUN
bjp-38807	71	21	3	3	NUM
bjp-38807	71	22	5	5	NUM
bjp-38807	71	23	34	34	NUM
bjp-38807	71	24	bangladesh	bangladesh	PROPN
bjp-38807	71	25	j	j	PROPN
bjp-38807	71	26	pharmacol	pharmacol	PROPN
bjp-38807	71	27	2019	2019	NUM
bjp-38807	71	28	;	;	PUNCT
bjp-38807	71	29	14	14	NUM
bjp-38807	71	30	:	:	SYM
bjp-38807	71	31	32	32	NUM
bjp-38807	71	32	-	-	SYM
bjp-38807	71	33	35	35	NUM
bjp-38807	71	34	author	author	NOUN
bjp-38807	71	35	info	info	NOUN
bjp-38807	71	36	guan	guan	PROPN
bjp-38807	71	37	wang	wang	PROPN
bjp-38807	71	38	(	(	PUNCT
bjp-38807	71	39	principal	principal	ADJ
bjp-38807	71	40	contact	contact	NOUN
bjp-38807	71	41	)	)	PUNCT
bjp-38807	71	42	e	e	NOUN
bjp-38807	71	43	-	-	NOUN
bjp-38807	71	44	mail	mail	NOUN
bjp-38807	71	45	:	:	PUNCT
bjp-38807	71	46	evabwalkerue@yahoo.com	evabwalkerue@yahoo.com	X
bjp-38807	71	47	possibly	possibly	ADV
bjp-38807	71	48	due	due	ADJ
bjp-38807	71	49	to	to	PART
bjp-38807	71	50	decrease	decrease	VERB
bjp-38807	71	51	release	release	NOUN
bjp-38807	71	52	of	of	ADP
bjp-38807	71	53	nitric	nitric	ADJ
bjp-38807	71	54	oxide	oxide	NOUN
bjp-38807	71	55	,	,	PUNCT
bjp-38807	71	56	which	which	PRON
bjp-38807	71	57	is	be	AUX
bjp-38807	71	58	essential	essential	ADJ
bjp-38807	71	59	for	for	ADP
bjp-38807	71	60	maintaining	maintain	VERB
bjp-38807	71	61	blood	blood	NOUN
bjp-38807	71	62	pressure	pressure	NOUN
bjp-38807	71	63	(	(	PUNCT
bjp-38807	71	64	kamba	kamba	NOUN
bjp-38807	71	65	and	and	CCONJ
bjp-38807	71	66	mcdonald	mcdonald	PROPN
bjp-38807	71	67	,	,	PUNCT
bjp-38807	71	68	2007	2007	NUM
bjp-38807	71	69	;	;	PUNCT
bjp-38807	71	70	lacouture	lacouture	NOUN
bjp-38807	71	71	et	et	PROPN
bjp-38807	71	72	al	al	PROPN
bjp-38807	71	73	.	.	PROPN
bjp-38807	71	74	,	,	PUNCT
bjp-38807	71	75	2008	2008	NUM
bjp-38807	71	76	)	)	PUNCT
bjp-38807	71	77	.	.	PUNCT
bjp-38807	72	1	hand	hand	NOUN
bjp-38807	72	2	-	-	PUNCT
bjp-38807	72	3	foot	foot	NOUN
bjp-38807	72	4	-	-	PUNCT
bjp-38807	72	5	skin	skin	NOUN
bjp-38807	72	6	-reaction	-reaction	NOUN
bjp-38807	72	7	and	and	CCONJ
bjp-38807	72	8	proteinuria	proteinuria	NOUN
bjp-38807	72	9	occurred	occur	VERB
bjp-38807	72	10	after	after	ADP
bjp-38807	72	11	treatment	treatment	NOUN
bjp-38807	72	12	is	be	AUX
bjp-38807	72	13	possibly	possibly	ADV
bjp-38807	72	14	due	due	ADJ
bjp-38807	72	15	to	to	ADP
bjp-38807	72	16	the	the	DET
bjp-38807	72	17	inhibition	inhibition	NOUN
bjp-38807	72	18	of	of	ADP
bjp-38807	72	19	vegf	vegf	NOUN
bjp-38807	72	20	receptors	receptor	NOUN
bjp-38807	72	21	(	(	PUNCT
bjp-38807	72	22	kamba	kamba	NOUN
bjp-38807	72	23	and	and	CCONJ
bjp-38807	72	24	mcdonald	mcdonald	PROPN
bjp-38807	72	25	,	,	PUNCT
bjp-38807	72	26	2007	2007	NUM
bjp-38807	72	27	;	;	PUNCT
bjp-38807	72	28	lacouture	lacouture	NOUN
bjp-38807	72	29	et	et	PROPN
bjp-38807	72	30	al	al	PROPN
bjp-38807	72	31	.	.	PROPN
bjp-38807	72	32	,	,	PUNCT
bjp-38807	72	33	2008	2008	NUM
bjp-38807	72	34	)	)	PUNCT
bjp-38807	72	35	.	.	PUNCT
bjp-38807	73	1	no	no	DET
bjp-38807	73	2	severe	severe	ADJ
bjp-38807	73	3	and	and	CCONJ
bjp-38807	73	4	fatal	fatal	ADJ
bjp-38807	73	5	treatment	treatment	NOUN
bjp-38807	73	6	-	-	PUNCT
bjp-38807	73	7	related	relate	VERB
bjp-38807	73	8	toxicities	toxicity	NOUN
bjp-38807	73	9	have	have	AUX
bjp-38807	73	10	been	be	AUX
bjp-38807	73	11	reported	report	VERB
bjp-38807	73	12	in	in	ADP
bjp-38807	73	13	patients	patient	NOUN
bjp-38807	73	14	treated	treat	VERB
bjp-38807	73	15	with	with	ADP
bjp-38807	73	16	regorafenib	regorafenib	NOUN
bjp-38807	73	17	.	.	PUNCT
bjp-38807	74	1	how	how	SCONJ
bjp-38807	74	2	-ever	-ever	ADV
bjp-38807	74	3	,	,	PUNCT
bjp-38807	74	4	it	it	PRON
bjp-38807	74	5	has	have	AUX
bjp-38807	74	6	been	be	AUX
bjp-38807	74	7	observed	observe	VERB
bjp-38807	74	8	with	with	ADP
bjp-38807	74	9	other	other	ADJ
bjp-38807	74	10	small	small	ADJ
bjp-38807	74	11	molecule	molecule	NOUN
bjp-38807	74	12	vegfr	vegfr	NOUN
bjp-38807	74	13	inhibitors	inhibitor	NOUN
bjp-38807	74	14	(	(	PUNCT
bjp-38807	74	15	lacouture	lacouture	NOUN
bjp-38807	74	16	et	et	PROPN
bjp-38807	74	17	al	al	PROPN
bjp-38807	74	18	.	.	PROPN
bjp-38807	74	19	,	,	PUNCT
bjp-38807	74	20	2008	2008	NUM
bjp-38807	74	21	)	)	PUNCT
bjp-38807	74	22	.	.	PUNCT
bjp-38807	75	1	overall	overall	ADV
bjp-38807	75	2	,	,	PUNCT
bjp-38807	75	3	regorafenib	regorafenib	NOUN
bjp-38807	75	4	appeared	appear	VERB
bjp-38807	75	5	efficacious	efficacious	ADJ
bjp-38807	75	6	and	and	CCONJ
bjp-38807	75	7	have	have	VERB
bjp-38807	75	8	a	a	DET
bjp-38807	75	9	manageable	manageable	ADJ
bjp-38807	75	10	safety	safety	NOUN
bjp-38807	75	11	profile	profile	NOUN
bjp-38807	75	12	and	and	CCONJ
bjp-38807	75	13	well	well	ADV
bjp-38807	75	14	tolerated	tolerate	VERB
bjp-38807	75	15	in	in	ADP
bjp-38807	75	16	the	the	DET
bjp-38807	75	17	treatment	treatment	NOUN
bjp-38807	75	18	population	population	NOUN
bjp-38807	75	19	.	.	PUNCT
bjp-38807	76	1	the	the	DET
bjp-38807	76	2	majority	majority	NOUN
bjp-38807	76	3	of	of	ADP
bjp-38807	76	4	adverse	adverse	ADJ
bjp-38807	76	5	events	event	NOUN
bjp-38807	76	6	were	be	AUX
bjp-38807	76	7	associated	associate	VERB
bjp-38807	76	8	with	with	ADP
bjp-38807	76	9	the	the	DET
bjp-38807	76	10	mechanism	mechanism	NOUN
bjp-38807	76	11	of	of	ADP
bjp-38807	76	12	action	action	NOUN
bjp-38807	76	13	of	of	ADP
bjp-38807	76	14	the	the	DET
bjp-38807	76	15	regorafenib	regorafenib	NOUN
bjp-38807	76	16	,	,	PUNCT
bjp-38807	76	17	and	and	CCONJ
bjp-38807	76	18	consistent	consistent	ADJ
bjp-38807	76	19	with	with	ADP
bjp-38807	76	20	those	those	PRON
bjp-38807	76	21	of	of	ADP
bjp-38807	76	22	its	its	PRON
bjp-38807	76	23	therapeutic	therapeutic	ADJ
bjp-38807	76	24	class	class	NOUN
bjp-38807	76	25	.	.	PUNCT
bjp-38807	77	1	also	also	ADV
bjp-38807	77	2	,	,	PUNCT
bjp-38807	77	3	regorafenib	regorafenib	NOUN
bjp-38807	77	4	demonstrated	demonstrate	VERB
bjp-38807	77	5	a	a	DET
bjp-38807	77	6	significant	significant	ADJ
bjp-38807	77	7	and	and	CCONJ
bjp-38807	77	8	clinically	clinically	ADV
bjp-38807	77	9	benefit	benefit	VERB
bjp-38807	77	10	in	in	ADP
bjp-38807	77	11	terms	term	NOUN
bjp-38807	77	12	of	of	ADP
bjp-38807	77	13	overall	overall	ADJ
bjp-38807	77	14	survival	survival	NOUN
bjp-38807	77	15	and	and	CCONJ
bjp-38807	77	16	progression	progression	NOUN
bjp-38807	77	17	-	-	PUNCT
bjp-38807	77	18	free	free	ADJ
bjp-38807	77	19	survival	survival	NOUN
bjp-38807	77	20	as	as	SCONJ
bjp-38807	77	21	compared	compare	VERB
bjp-38807	77	22	with	with	ADP
bjp-38807	77	23	dinutuximab	dinutuximab	NOUN
bjp-38807	77	24	with	with	ADP
bjp-38807	77	25	chemotherapy	chemotherapy	NOUN
bjp-38807	77	26	in	in	ADP
bjp-38807	77	27	chinese	chinese	ADJ
bjp-38807	77	28	children	child	NOUN
bjp-38807	77	29	with	with	ADP
bjp-38807	77	30	advanced	advanced	ADJ
bjp-38807	77	31	neuroblastoma	neuroblastoma	NOUN
bjp-38807	77	32	.	.	PUNCT
bjp-38807	78	1	conclusion	conclusion	NOUN
bjp-38807	78	2	regorafenib	regorafenib	PROPN
bjp-38807	78	3	appears	appear	VERB
bjp-38807	78	4	efficacious	efficacious	ADJ
bjp-38807	78	5	and	and	CCONJ
bjp-38807	78	6	has	have	VERB
bjp-38807	78	7	a	a	DET
bjp-38807	78	8	manageable	manageable	ADJ
bjp-38807	78	9	safety	safety	NOUN
bjp-38807	78	10	profile	profile	NOUN
bjp-38807	78	11	in	in	ADP
bjp-38807	78	12	chinese	chinese	ADJ
bjp-38807	78	13	children	child	NOUN
bjp-38807	78	14	with	with	ADP
bjp-38807	78	15	advanced	advanced	ADJ
bjp-38807	78	16	neuroblastoma	neuroblastoma	NOUN
bjp-38807	78	17	.	.	PUNCT
bjp-38807	79	1	ethical	ethical	ADJ
bjp-38807	79	2	issue	issue	NOUN
bjp-38807	79	3	written	write	VERB
bjp-38807	79	4	informed	informed	ADJ
bjp-38807	79	5	consent	consent	NOUN
bjp-38807	79	6	was	be	AUX
bjp-38807	79	7	taken	take	VERB
bjp-38807	79	8	from	from	ADP
bjp-38807	79	9	each	each	DET
bjp-38807	79	10	patient	patient	NOUN
bjp-38807	79	11	and	and	CCONJ
bjp-38807	79	12	ethics	ethic	NOUN
bjp-38807	79	13	committee	committee	PROPN
bjp-38807	79	14	approval	approval	NOUN
bjp-38807	79	15	was	be	AUX
bjp-38807	79	16	obtained	obtain	VERB
bjp-38807	79	17	from	from	ADP
bjp-38807	79	18	the	the	DET
bjp-38807	79	19	institutional	institutional	ADJ
bjp-38807	79	20	ethics	ethic	NOUN
bjp-38807	79	21	committee	committee	PROPN
bjp-38807	79	22	of	of	ADP
bjp-38807	79	23	dezhou	dezhou	PROPN
bjp-38807	79	24	people	people	NOUN
bjp-38807	79	25	's	's	PART
bjp-38807	79	26	hospital	hospital	NOUN
bjp-38807	79	27	.	.	PUNCT
bjp-38807	80	1	references	reference	NOUN
bjp-38807	80	2	boubaker	boubaker	NOUN
bjp-38807	80	3	a	a	PRON
bjp-38807	80	4	,	,	PUNCT
bjp-38807	80	5	bischof	bischof	ADJ
bjp-38807	80	6	da	da	X
bjp-38807	80	7	.	.	PUNCT
bjp-38807	80	8	nuclear	nuclear	ADJ
bjp-38807	80	9	medicine	medicine	NOUN
bjp-38807	80	10	procedures	procedure	NOUN
bjp-38807	80	11	and	and	CCONJ
bjp-38807	80	12	neuroblastoma	neuroblastoma	NOUN
bjp-38807	80	13	in	in	ADP
bjp-38807	80	14	childhood	childhood	NOUN
bjp-38807	80	15	:	:	PUNCT
bjp-38807	80	16	their	their	PRON
bjp-38807	80	17	value	value	NOUN
bjp-38807	80	18	in	in	ADP
bjp-38807	80	19	the	the	DET
bjp-38807	80	20	diagnosis	diagnosis	NOUN
bjp-38807	80	21	,	,	PUNCT
bjp-38807	80	22	staging	staging	NOUN
bjp-38807	80	23	and	and	CCONJ
bjp-38807	80	24	assessment	assessment	NOUN
bjp-38807	80	25	of	of	ADP
bjp-38807	80	26	response	response	NOUN
bjp-38807	80	27	to	to	ADP
bjp-38807	80	28	therapy	therapy	NOUN
bjp-38807	80	29	.	.	PUNCT
bjp-38807	81	1	q	q	PUNCT
bjp-38807	82	1	j	j	PROPN
bjp-38807	82	2	nucl	nucl	PROPN
bjp-38807	82	3	med	me	VERB
bjp-38807	82	4	.	.	PUNCT
bjp-38807	82	5	2003	2003	NUM
bjp-38807	82	6	;	;	PUNCT
bjp-38807	82	7	47	47	NUM
bjp-38807	82	8	:	:	SYM
bjp-38807	82	9	31	31	NUM
bjp-38807	82	10	-	-	SYM
bjp-38807	82	11	40	40	NUM
bjp-38807	82	12	.	.	PUNCT
bjp-38807	83	1	cao	cao	PROPN
bjp-38807	83	2	j	j	PROPN
bjp-38807	83	3	,	,	PUNCT
bjp-38807	83	4	zhang	zhang	PROPN
bjp-38807	83	5	j	j	PROPN
bjp-38807	83	6	,	,	PUNCT
bjp-38807	83	7	peng	peng	PROPN
bjp-38807	83	8	w.	w.	PROPN
bjp-38807	83	9	a	a	DET
bjp-38807	83	10	phase	phase	NOUN
bjp-38807	83	11	i	i	PRON
bjp-38807	83	12	study	study	VERB
bjp-38807	83	13	of	of	ADP
bjp-38807	83	14	safety	safety	NOUN
bjp-38807	83	15	and	and	CCONJ
bjp-38807	83	16	pharmacokinetics	pharmacokinetic	NOUN
bjp-38807	83	17	of	of	ADP
bjp-38807	83	18	fruquintinib	fruquintinib	NOUN
bjp-38807	83	19	,	,	PUNCT
bjp-38807	83	20	a	a	DET
bjp-38807	83	21	novel	novel	ADJ
bjp-38807	83	22	selective	selective	ADJ
bjp-38807	83	23	inhibitor	inhibitor	NOUN
bjp-38807	83	24	of	of	ADP
bjp-38807	83	25	vascular	vascular	ADJ
bjp-38807	83	26	endothelial	endothelial	ADJ
bjp-38807	83	27	growth	growth	NOUN
bjp-38807	83	28	factor	factor	NOUN
bjp-38807	83	29	receptor-1	receptor-1	NOUN
bjp-38807	83	30	,	,	PUNCT
bjp-38807	83	31	-2	-2	INTJ
bjp-38807	83	32	,	,	PUNCT
bjp-38807	83	33	and	and	CCONJ
bjp-38807	83	34	-3	-3	PUNCT
bjp-38807	83	35	tyrosine	tyrosine	NOUN
bjp-38807	83	36	kinases	kinase	NOUN
bjp-38807	83	37	in	in	ADP
bjp-38807	83	38	chinese	chinese	ADJ
bjp-38807	83	39	patients	patient	NOUN
bjp-38807	83	40	with	with	ADP
bjp-38807	83	41	advanced	advanced	ADJ
bjp-38807	83	42	solid	solid	ADJ
bjp-38807	83	43	tumors	tumor	NOUN
bjp-38807	83	44	.	.	PUNCT
bjp-38807	84	1	cancer	cancer	NOUN
bjp-38807	84	2	chemother	chemother	PROPN
bjp-38807	84	3	pharmacol	pharmacol	PROPN
bjp-38807	84	4	.	.	PROPN
bjp-38807	85	1	2016	2016	NUM
bjp-38807	85	2	;	;	PUNCT
bjp-38807	85	3	78	78	NUM
bjp-38807	85	4	:	:	PUNCT
bjp-38807	85	5	259	259	NUM
bjp-38807	85	6	-	-	SYM
bjp-38807	85	7	69	69	NUM
bjp-38807	85	8	.	.	PUNCT
bjp-38807	86	1	escudier	escudi	ADJ
bjp-38807	86	2	b	b	NOUN
bjp-38807	86	3	,	,	PUNCT
bjp-38807	86	4	eisen	eisen	PROPN
bjp-38807	86	5	t	t	PROPN
bjp-38807	86	6	,	,	PUNCT
bjp-38807	86	7	stadler	stadler	PROPN
bjp-38807	86	8	wm	wm	PROPN
bjp-38807	86	9	,	,	PUNCT
bjp-38807	86	10	szczylik	szczylik	VERB
bjp-38807	86	11	c	c	NOUN
bjp-38807	86	12	,	,	PUNCT
bjp-38807	86	13	oudard	oudard	ADJ
bjp-38807	86	14	s	s	NOUN
bjp-38807	86	15	,	,	PUNCT
bjp-38807	86	16	siebels	siebel	NOUN
bjp-38807	86	17	m	m	PROPN
bjp-38807	86	18	,	,	PUNCT
bjp-38807	86	19	negrier	negrier	NOUN
bjp-38807	86	20	s	s	PROPN
bjp-38807	86	21	,	,	PUNCT
bjp-38807	86	22	chevreau	chevreau	NOUN
bjp-38807	86	23	c	c	NOUN
bjp-38807	86	24	,	,	PUNCT
bjp-38807	86	25	solska	solska	PROPN
bjp-38807	86	26	e	e	NOUN
bjp-38807	86	27	,	,	PUNCT
bjp-38807	86	28	desai	desai	PROPN
bjp-38807	86	29	aa	aa	PROPN
bjp-38807	86	30	,	,	PUNCT
bjp-38807	86	31	rolland	rolland	PROPN
bjp-38807	86	32	f	f	PROPN
bjp-38807	86	33	,	,	PUNCT
bjp-38807	86	34	demkow	demkow	PROPN
bjp-38807	86	35	t	t	PROPN
bjp-38807	86	36	,	,	PUNCT
bjp-38807	86	37	hutson	hutson	PROPN
bjp-38807	86	38	te	te	PROPN
bjp-38807	86	39	,	,	PUNCT
bjp-38807	86	40	gore	gore	PROPN
bjp-38807	86	41	m	m	PROPN
bjp-38807	86	42	,	,	PUNCT
bjp-38807	86	43	freeman	freeman	PROPN
bjp-38807	86	44	s	s	PROPN
bjp-38807	86	45	,	,	PUNCT
bjp-38807	86	46	schwartz	schwartz	PROPN
bjp-38807	86	47	b	b	PROPN
bjp-38807	86	48	,	,	PUNCT
bjp-38807	86	49	shan	shan	PROPN
bjp-38807	86	50	m	m	PROPN
bjp-38807	86	51	,	,	PUNCT
bjp-38807	86	52	simantov	simantov	ADJ
bjp-38807	86	53	r	r	PROPN
bjp-38807	86	54	,	,	PUNCT
bjp-38807	86	55	bukowski	bukowski	PROPN
bjp-38807	86	56	rm	rm	PROPN
bjp-38807	86	57	;	;	PUNCT
bjp-38807	86	58	target	target	NOUN
bjp-38807	86	59	study	study	NOUN
bjp-38807	86	60	group	group	NOUN
bjp-38807	86	61	.	.	PUNCT
bjp-38807	87	1	sorafenib	sorafenib	PROPN
bjp-38807	87	2	in	in	ADP
bjp-38807	87	3	advanced	advanced	ADJ
bjp-38807	87	4	clear	clear	ADJ
bjp-38807	87	5	-	-	PUNCT
bjp-38807	87	6	cell	cell	NOUN
bjp-38807	87	7	renal	renal	ADJ
bjp-38807	87	8	-	-	PUNCT
bjp-38807	87	9	cell	cell	NOUN
bjp-38807	87	10	carcinoma	carcinoma	NOUN
bjp-38807	87	11	.	.	PUNCT
bjp-38807	88	1	n	n	PRON
bjp-38807	88	2	engl	engl	PROPN
bjp-38807	88	3	j	j	PROPN
bjp-38807	88	4	med	med	PROPN
bjp-38807	88	5	.	.	PUNCT
bjp-38807	88	6	2007	2007	NUM
bjp-38807	88	7	;	;	PUNCT
bjp-38807	88	8	356	356	NUM
bjp-38807	88	9	:	:	SYM
bjp-38807	88	10	125	125	NUM
bjp-38807	88	11	-	-	SYM
bjp-38807	88	12	34	34	NUM
bjp-38807	88	13	.	.	PUNCT
bjp-38807	89	1	grothey	grothey	PROPN
bjp-38807	89	2	a	a	PROPN
bjp-38807	89	3	,	,	PUNCT
bjp-38807	89	4	van	van	PROPN
bjp-38807	89	5	cutsem	cutsem	PROPN
bjp-38807	89	6	e	e	NOUN
bjp-38807	89	7	,	,	PUNCT
bjp-38807	89	8	sobrero	sobrero	PROPN
bjp-38807	89	9	a.	a.	NOUN
bjp-38807	89	10	regorafenib	regorafenib	PROPN
bjp-38807	89	11	monotherapy	monotherapy	NOUN
bjp-38807	89	12	for	for	ADP
bjp-38807	89	13	previously	previously	ADV
bjp-38807	89	14	treated	treat	VERB
bjp-38807	89	15	metastatic	metastatic	ADJ
bjp-38807	89	16	colorectal	colorectal	ADJ
bjp-38807	89	17	cancer	cancer	NOUN
bjp-38807	89	18	(	(	PUNCT
bjp-38807	89	19	correct	correct	ADJ
bjp-38807	89	20	):	):	PUNCT
bjp-38807	89	21	an	an	DET
bjp-38807	89	22	international	international	ADJ
bjp-38807	89	23	,	,	PUNCT
bjp-38807	89	24	multicentre	multicentre	NOUN
bjp-38807	89	25	,	,	PUNCT
bjp-38807	89	26	randomised	randomise	VERB
bjp-38807	89	27	,	,	PUNCT
bjp-38807	89	28	placebo	placebo	NOUN
bjp-38807	89	29	-	-	PUNCT
bjp-38807	89	30	controlled	control	VERB
bjp-38807	89	31	,	,	PUNCT
bjp-38807	89	32	phase	phase	NOUN
bjp-38807	89	33	3	3	NUM
bjp-38807	89	34	trial	trial	NOUN
bjp-38807	89	35	.	.	PUNCT
bjp-38807	90	1	lancet	lancet	PROPN
bjp-38807	90	2	2013	2013	NUM
bjp-38807	90	3	;	;	PUNCT
bjp-38807	90	4	381	381	NUM
bjp-38807	90	5	:	:	PUNCT
bjp-38807	90	6	303	303	NUM
bjp-38807	90	7	-	-	SYM
bjp-38807	90	8	12	12	NUM
bjp-38807	90	9	.	.	PUNCT
bjp-38807	91	1	hiorns	hiorns	PROPN
bjp-38807	91	2	mp	mp	PROPN
bjp-38807	91	3	,	,	PUNCT
bjp-38807	91	4	owens	owens	PROPN
bjp-38807	91	5	cm	cm	PROPN
bjp-38807	91	6	.	.	PUNCT
bjp-38807	92	1	radiology	radiology	NOUN
bjp-38807	92	2	of	of	ADP
bjp-38807	92	3	neuroblastoma	neuroblastoma	NOUN
bjp-38807	92	4	in	in	ADP
bjp-38807	92	5	children	child	NOUN
bjp-38807	92	6	.	.	PUNCT
bjp-38807	93	1	eur	eur	ADJ
bjp-38807	93	2	radiol	radiol	NOUN
bjp-38807	93	3	.	.	PUNCT
bjp-38807	94	1	2001	2001	NUM
bjp-38807	94	2	;	;	PUNCT
bjp-38807	94	3	11	11	NUM
bjp-38807	94	4	:	:	SYM
bjp-38807	94	5	2071	2071	NUM
bjp-38807	94	6	-	-	SYM
bjp-38807	94	7	81	81	NUM
bjp-38807	94	8	.	.	PUNCT
bjp-38807	95	1	kamba	kamba	PROPN
bjp-38807	95	2	t	t	PROPN
bjp-38807	95	3	,	,	PUNCT
bjp-38807	95	4	mcdonald	mcdonald	PROPN
bjp-38807	95	5	dm	dm	PROPN
bjp-38807	95	6	.	.	PUNCT
bjp-38807	95	7	mechanisms	mechanism	NOUN
bjp-38807	95	8	of	of	ADP
bjp-38807	95	9	adverse	adverse	ADJ
bjp-38807	95	10	effects	effect	NOUN
bjp-38807	95	11	of	of	ADP
bjp-38807	95	12	anti	anti	ADJ
bjp-38807	95	13	-	-	ADJ
bjp-38807	95	14	vegf	vegf	ADJ
bjp-38807	95	15	therapy	therapy	NOUN
bjp-38807	95	16	for	for	ADP
bjp-38807	95	17	cancer	cancer	NOUN
bjp-38807	95	18	.	.	PUNCT
bjp-38807	96	1	br	br	PROPN
bjp-38807	96	2	j	j	PROPN
bjp-38807	96	3	cancer	cancer	NOUN
bjp-38807	96	4	.	.	PUNCT
bjp-38807	97	1	2007	2007	NUM
bjp-38807	97	2	;	;	PUNCT
bjp-38807	97	3	96	96	NUM
bjp-38807	97	4	:	:	SYM
bjp-38807	97	5	1788	1788	NUM
bjp-38807	97	6	-	-	SYM
bjp-38807	97	7	95	95	NUM
bjp-38807	97	8	.	.	PUNCT
bjp-38807	98	1	kushner	kushner	PROPN
bjp-38807	98	2	bh	bh	PROPN
bjp-38807	98	3	.	.	PUNCT
bjp-38807	99	1	neuroblastoma	neuroblastoma	NOUN
bjp-38807	99	2	:	:	PUNCT
bjp-38807	99	3	a	a	DET
bjp-38807	99	4	disease	disease	NOUN
bjp-38807	99	5	requiring	require	VERB
bjp-38807	99	6	a	a	DET
bjp-38807	99	7	multitude	multitude	NOUN
bjp-38807	99	8	of	of	ADP
bjp-38807	99	9	imaging	imaging	NOUN
bjp-38807	99	10	studies	study	NOUN
bjp-38807	99	11	.	.	PUNCT
bjp-38807	100	1	j	j	PROPN
bjp-38807	100	2	nucl	nucl	PROPN
bjp-38807	100	3	med	med	PROPN
bjp-38807	100	4	.	.	PUNCT
bjp-38807	100	5	2004	2004	NUM
bjp-38807	100	6	;	;	PUNCT
bjp-38807	100	7	45	45	NUM
bjp-38807	100	8	:	:	SYM
bjp-38807	100	9	1172	1172	NUM
bjp-38807	100	10	-	-	SYM
bjp-38807	100	11	88	88	NUM
bjp-38807	100	12	.	.	PUNCT
bjp-38807	101	1	lacouture	lacouture	NOUN
bjp-38807	101	2	me	i	PRON
bjp-38807	101	3	,	,	PUNCT
bjp-38807	101	4	reilly	reilly	ADV
bjp-38807	101	5	lm	lm	PROPN
bjp-38807	101	6	,	,	PUNCT
bjp-38807	101	7	gerami	gerami	ADJ
bjp-38807	101	8	p.	p.	NOUN
bjp-38807	101	9	hand	hand	NOUN
bjp-38807	101	10	foot	foot	NOUN
bjp-38807	101	11	skin	skin	NOUN
bjp-38807	101	12	reaction	reaction	NOUN
bjp-38807	101	13	in	in	ADP
bjp-38807	101	14	cancer	cancer	NOUN
bjp-38807	101	15	patients	patient	NOUN
bjp-38807	101	16	treated	treat	VERB
bjp-38807	101	17	with	with	ADP
bjp-38807	101	18	the	the	DET
bjp-38807	101	19	multikinase	multikinase	NOUN
bjp-38807	101	20	inhibitors	inhibitor	NOUN
bjp-38807	101	21	sorafenib	sorafenib	NOUN
bjp-38807	101	22	and	and	CCONJ
bjp-38807	101	23	sunitinib	sunitinib	NOUN
bjp-38807	101	24	.	.	PUNCT
bjp-38807	102	1	ann	ann	PROPN
bjp-38807	102	2	oncol	oncol	PROPN
bjp-38807	102	3	.	.	PUNCT
bjp-38807	103	1	2008	2008	NUM
bjp-38807	103	2	;	;	PUNCT
bjp-38807	103	3	19	19	NUM
bjp-38807	103	4	:	:	SYM
bjp-38807	103	5	1955	1955	NUM
bjp-38807	103	6	-	-	SYM
bjp-38807	103	7	61	61	NUM
bjp-38807	103	8	.	.	PUNCT
bjp-38807	104	1	li	li	PROPN
bjp-38807	104	2	j	j	PROPN
bjp-38807	104	3	,	,	PUNCT
bjp-38807	104	4	qin	qin	PROPN
bjp-38807	104	5	s	s	PROPN
bjp-38807	104	6	,	,	PUNCT
bjp-38807	104	7	xu	xu	PROPN
bjp-38807	104	8	r.	r.	PROPN
bjp-38807	104	9	effect	effect	NOUN
bjp-38807	104	10	of	of	ADP
bjp-38807	104	11	fruquintinib	fruquintinib	NOUN
bjp-38807	104	12	vs	vs	ADP
bjp-38807	104	13	placebo	placebo	NOUN
bjp-38807	104	14	on	on	ADP
bjp-38807	104	15	overall	overall	ADJ
bjp-38807	104	16	survival	survival	NOUN
bjp-38807	104	17	in	in	ADP
bjp-38807	104	18	patients	patient	NOUN
bjp-38807	104	19	with	with	ADP
bjp-38807	104	20	previously	previously	ADV
bjp-38807	104	21	treated	treat	VERB
bjp-38807	104	22	metastatic	metastatic	ADJ
bjp-38807	104	23	colorectal	colorectal	ADJ
bjp-38807	104	24	cancer	cancer	NOUN
bjp-38807	104	25	the	the	DET
bjp-38807	104	26	fresco	fresco	NOUN
bjp-38807	104	27	randomized	randomize	VERB
bjp-38807	104	28	clinical	clinical	ADJ
bjp-38807	104	29	trial	trial	NOUN
bjp-38807	104	30	.	.	PUNCT
bjp-38807	105	1	jama	jama	PROPN
bjp-38807	105	2	.	.	PUNCT
bjp-38807	106	1	2018	2018	NUM
bjp-38807	106	2	;	;	PUNCT
bjp-38807	106	3	319	319	NUM
bjp-38807	106	4	:	:	PUNCT
bjp-38807	106	5	2486	2486	NUM
bjp-38807	106	6	-	-	SYM
bjp-38807	106	7	96	96	NUM
bjp-38807	106	8	.	.	PUNCT
bjp-38807	106	9	motzer	motzer	PROPN
bjp-38807	106	10	rj	rj	PROPN
bjp-38807	106	11	,	,	PUNCT
bjp-38807	106	12	hutson	hutson	PROPN
bjp-38807	106	13	te	te	PROPN
bjp-38807	106	14	,	,	PUNCT
bjp-38807	106	15	cella	cella	PROPN
bjp-38807	106	16	d.	d.	PROPN
bjp-38807	106	17	pazopanib	pazopanib	PROPN
bjp-38807	106	18	versus	versus	ADP
bjp-38807	106	19	sunitinib	sunitinib	NOUN
bjp-38807	106	20	in	in	ADP
bjp-38807	106	21	metastatic	metastatic	ADJ
bjp-38807	106	22	renal	renal	ADJ
bjp-38807	106	23	-	-	PUNCT
bjp-38807	106	24	cell	cell	NOUN
bjp-38807	106	25	carcinoma	carcinoma	NOUN
bjp-38807	106	26	.	.	PUNCT
bjp-38807	107	1	n	n	PRON
bjp-38807	107	2	engl	engl	PROPN
bjp-38807	107	3	j	j	PROPN
bjp-38807	107	4	med	med	PROPN
bjp-38807	107	5	.	.	PUNCT
bjp-38807	107	6	2013	2013	NUM
bjp-38807	107	7	;	;	PUNCT
bjp-38807	107	8	369	369	NUM
bjp-38807	107	9	:	:	SYM
bjp-38807	107	10	722	722	NUM
bjp-38807	107	11	–	–	SYM
bjp-38807	107	12	31	31	NUM
bjp-38807	107	13	.	.	PUNCT
bjp-38807	108	1	motzer	motzer	PROPN
bjp-38807	108	2	rj	rj	PROPN
bjp-38807	108	3	,	,	PUNCT
bjp-38807	108	4	hutson	hutson	PROPN
bjp-38807	108	5	te	te	PROPN
bjp-38807	108	6	,	,	PUNCT
bjp-38807	108	7	tomczak	tomczak	NOUN
bjp-38807	108	8	p.	p.	NOUN
bjp-38807	108	9	overall	overall	ADJ
bjp-38807	108	10	survival	survival	NOUN
bjp-38807	108	11	and	and	CCONJ
bjp-38807	108	12	updated	update	VERB
bjp-38807	108	13	results	result	NOUN
bjp-38807	108	14	for	for	ADP
bjp-38807	108	15	sunitinib	sunitinib	NOUN
bjp-38807	108	16	compared	compare	VERB
bjp-38807	108	17	with	with	ADP
bjp-38807	108	18	interferon	interferon	ADJ
bjp-38807	108	19	alfa	alfa	NOUN
bjp-38807	108	20	in	in	ADP
bjp-38807	108	21	patients	patient	NOUN
bjp-38807	108	22	with	with	ADP
bjp-38807	108	23	metastatic	metastatic	ADJ
bjp-38807	108	24	renal	renal	ADJ
bjp-38807	108	25	cell	cell	NOUN
bjp-38807	108	26	carcinoma	carcinoma	NOUN
bjp-38807	108	27	.	.	PUNCT
bjp-38807	109	1	j	j	PROPN
bjp-38807	109	2	clin	clin	PROPN
bjp-38807	109	3	oncol	oncol	PROPN
bjp-38807	109	4	.	.	PUNCT
bjp-38807	110	1	2009	2009	NUM
bjp-38807	110	2	;	;	PUNCT
bjp-38807	110	3	27	27	NUM
bjp-38807	110	4	:	:	SYM
bjp-38807	110	5	3584	3584	NUM
bjp-38807	110	6	-	-	SYM
bjp-38807	110	7	90	90	NUM
bjp-38807	110	8	.	.	PUNCT
bjp-38807	111	1	motzer	motzer	PROPN
bjp-38807	111	2	rj	rj	PROPN
bjp-38807	111	3	,	,	PUNCT
bjp-38807	111	4	hutson	hutson	PROPN
bjp-38807	111	5	te	te	PROPN
bjp-38807	111	6	,	,	PUNCT
bjp-38807	111	7	tomczak	tomczak	NOUN
bjp-38807	111	8	p.	p.	NOUN
bjp-38807	111	9	sunitinib	sunitinib	NOUN
bjp-38807	111	10	versus	versus	ADP
bjp-38807	111	11	interferon	interferon	ADJ
bjp-38807	111	12	alfa	alfa	NOUN
bjp-38807	111	13	in	in	ADP
bjp-38807	111	14	metastatic	metastatic	ADJ
bjp-38807	111	15	renal	renal	ADJ
bjp-38807	111	16	-	-	PUNCT
bjp-38807	111	17	cell	cell	NOUN
bjp-38807	111	18	carcinoma	carcinoma	NOUN
bjp-38807	111	19	.	.	PUNCT
bjp-38807	112	1	n	n	PRON
bjp-38807	112	2	engl	engl	PROPN
bjp-38807	112	3	j	j	PROPN
bjp-38807	112	4	med	med	PROPN
bjp-38807	112	5	.	.	PUNCT
bjp-38807	112	6	2007	2007	NUM
bjp-38807	112	7	;	;	PUNCT
bjp-38807	112	8	356	356	NUM
bjp-38807	112	9	:	:	PUNCT
bjp-38807	112	10	115–24	115–24	NUM
bjp-38807	112	11	.	.	PUNCT
bjp-38807	113	1	xu	xu	PROPN
bjp-38807	113	2	rh	rh	PROPN
bjp-38807	113	3	,	,	PUNCT
bjp-38807	113	4	jin	jin	PROPN
bjp-38807	113	5	l	l	PROPN
bjp-38807	113	6	,	,	PUNCT
bjp-38807	113	7	yuxian	yuxian	PROPN
bjp-38807	113	8	b.	b.	PROPN
bjp-38807	113	9	safety	safety	PROPN
bjp-38807	113	10	and	and	CCONJ
bjp-38807	113	11	efficacy	efficacy	NOUN
bjp-38807	113	12	of	of	ADP
bjp-38807	113	13	fruquin	fruquin	NOUN
bjp-38807	113	14	-	-	PUNCT
bjp-38807	113	15	tinib	tinib	NOUN
bjp-38807	113	16	in	in	ADP
bjp-38807	113	17	patients	patient	NOUN
bjp-38807	113	18	with	with	ADP
bjp-38807	113	19	previously	previously	ADV
bjp-38807	113	20	treated	treat	VERB
bjp-38807	113	21	metastatic	metastatic	ADJ
bjp-38807	113	22	colorectal	colorectal	ADJ
bjp-38807	113	23	cancer	cancer	NOUN
bjp-38807	113	24	:	:	PUNCT
bjp-38807	113	25	a	a	DET
bjp-38807	113	26	phase	phase	NOUN
bjp-38807	113	27	ib	ib	NOUN
bjp-38807	113	28	study	study	NOUN
bjp-38807	113	29	and	and	CCONJ
bjp-38807	113	30	a	a	DET
bjp-38807	113	31	randomized	randomized	ADJ
bjp-38807	113	32	double	double	ADJ
bjp-38807	113	33	-	-	PUNCT
bjp-38807	113	34	blind	blind	ADJ
bjp-38807	113	35	phase	phase	NOUN
bjp-38807	113	36	ii	ii	PROPN
bjp-38807	113	37	study	study	NOUN
bjp-38807	113	38	.	.	PUNCT
bjp-38807	114	1	j	j	PROPN
bjp-38807	114	2	hematol	hematol	PROPN
bjp-38807	114	3	oncol	oncol	PROPN
bjp-38807	114	4	.	.	PUNCT
bjp-38807	115	1	2017	2017	NUM
bjp-38807	115	2	;	;	PUNCT
bjp-38807	115	3	10	10	NUM
bjp-38807	115	4	:	:	SYM
bjp-38807	115	5	22	22	NUM
bjp-38807	115	6	.	.	PUNCT
bjp-38807	116	1	schwab	schwab	PROPN
bjp-38807	116	2	m	m	PROPN
bjp-38807	116	3	,	,	PUNCT
bjp-38807	116	4	westermann	westermann	PROPN
bjp-38807	116	5	f	f	PROPN
bjp-38807	116	6	,	,	PUNCT
bjp-38807	116	7	hero	hero	NOUN
bjp-38807	116	8	b	b	PROPN
bjp-38807	116	9	,	,	PUNCT
bjp-38807	116	10	berthold	berthold	PROPN
bjp-38807	116	11	f.	f.	PROPN
bjp-38807	116	12	neuroblastoma	neuroblastoma	PROPN
bjp-38807	116	13	:	:	PUNCT
bjp-38807	116	14	biology	biology	NOUN
bjp-38807	116	15	and	and	CCONJ
bjp-38807	116	16	molecular	molecular	ADJ
bjp-38807	116	17	and	and	CCONJ
bjp-38807	116	18	chromosomal	chromosomal	ADJ
bjp-38807	116	19	pathology	pathology	NOUN
bjp-38807	116	20	.	.	PUNCT
bjp-38807	117	1	lancet	lancet	PROPN
bjp-38807	117	2	oncol	oncol	PROPN
bjp-38807	117	3	.	.	PUNCT
bjp-38807	118	1	2003	2003	NUM
bjp-38807	118	2	;	;	PUNCT
bjp-38807	118	3	4	4	NUM
bjp-38807	118	4	:	:	PUNCT
bjp-38807	118	5	472–80	472–80	NUM
bjp-38807	118	6	.	.	PUNCT
bjp-38807	119	1	table	table	NOUN
bjp-38807	119	2	iii	iii	NUM
bjp-38807	119	3	comparison	comparison	NOUN
bjp-38807	119	4	of	of	ADP
bjp-38807	119	5	treatment	treatment	NOUN
bjp-38807	119	6	-	-	PUNCT
bjp-38807	119	7	related	relate	VERB
bjp-38807	119	8	adverse	adverse	ADJ
bjp-38807	119	9	events	event	NOUN
bjp-38807	119	10	in	in	ADP
bjp-38807	119	11	children	child	NOUN
bjp-38807	119	12	with	with	ADP
bjp-38807	119	13	neuroblastoma	neuroblastoma	ADJ
bjp-38807	119	14	(	(	PUNCT
bjp-38807	119	15	safety	safety	NOUN
bjp-38807	119	16	population	population	NOUN
bjp-38807	119	17	)	)	PUNCT
bjp-38807	119	18	best	good	ADJ
bjp-38807	119	19	supportive	supportive	ADJ
bjp-38807	119	20	care	care	NOUN
bjp-38807	119	21	plus	plus	CCONJ
bjp-38807	119	22	adverse	adverse	ADJ
bjp-38807	119	23	events	event	NOUN
bjp-38807	119	24	regorafenib	regorafenib	NOUN
bjp-38807	119	25	dinutuximab	dinutuximab	NOUN
bjp-38807	119	26	plus	plus	CCONJ
bjp-38807	119	27	chemotherapy	chemotherapy	NOUN
bjp-38807	119	28	hypertension	hypertension	NOUN
bjp-38807	119	29	13	13	NUM
bjp-38807	119	30	11	11	NUM
bjp-38807	119	31	hand	hand	NOUN
bjp-38807	119	32	-	-	PUNCT
bjp-38807	119	33	foot	foot	NOUN
bjp-38807	119	34	skin	skin	NOUN
bjp-38807	119	35	reaction	reaction	NOUN
bjp-38807	119	36	14	14	NUM
bjp-38807	119	37	12	12	NUM
bjp-38807	119	38	rash	rash	NOUN
bjp-38807	119	39	12	12	NUM
bjp-38807	119	40	9	9	NUM
bjp-38807	119	41	proteinuria	proteinuria	NOUN
bjp-38807	119	42	19	19	NUM
bjp-38807	119	43	18	18	NUM
bjp-38807	119	44	occult	occult	NOUN
bjp-38807	119	45	blood	blood	NOUN
bjp-38807	119	46	positive	positive	ADJ
bjp-38807	119	47	8	8	NUM
bjp-38807	119	48	12	12	NUM
bjp-38807	119	49	epistaxis	epistaxis	ADJ
bjp-38807	119	50	9	9	NUM
bjp-38807	119	51	19	19	NUM
bjp-38807	119	52	hematuria	hematuria	NOUN
bjp-38807	119	53	12	12	NUM
bjp-38807	119	54	12	12	NUM
bjp-38807	119	55	hypothyroidism	hypothyroidism	NOUN
bjp-38807	119	56	20	20	NUM
bjp-38807	119	57	19	19	NUM
bjp-38807	119	58	n=30	n=30	NOUN
bjp-38807	119	59	in	in	ADP
bjp-38807	119	60	each	each	DET
bjp-38807	119	61	group	group	NOUN
bjp-38807	119	62	;	;	PUNCT
bjp-38807	119	63	no	no	DET
bjp-38807	119	64	grade	grade	NOUN
bjp-38807	119	65	5	5	NUM
bjp-38807	119	66	treatment	treatment	NOUN
bjp-38807	119	67	-	-	PUNCT
bjp-38807	119	68	related	relate	VERB
bjp-38807	119	69	treatmentemergent	treatmentemergent	ADJ
bjp-38807	119	70	adverse	adverse	ADJ
bjp-38807	119	71	event	event	NOUN
bjp-38807	119	72	occurred	occur	VERB
bjp-38807	119	73	at	at	ADP
bjp-38807	119	74	an	an	DET
bjp-38807	119	75	overall	overall	ADJ
bjp-38807	119	76	rate	rate	NOUN
bjp-38807	119	77	≥5	≥5	NOUN
bjp-38807	119	78	%	%	NOUN
bjp-38807	119	79	bangladesh	bangladesh	NOUN
bjp-38807	119	80	j	j	PROPN
bjp-38807	119	81	pharmacol	pharmacol	PROPN
bjp-38807	119	82	2019	2019	NUM
bjp-38807	119	83	;	;	PUNCT
bjp-38807	119	84	14	14	NUM
bjp-38807	119	85	:	:	SYM
bjp-38807	119	86	32	32	NUM
bjp-38807	119	87	-	-	SYM
bjp-38807	119	88	35	35	NUM
bjp-38807	119	89	35	35	NUM
bjp-38807	119	90	dateprinted	dateprinte	VERB
bjp-38807	119	91	:	:	PUNCT
bjp-38807	119	92	this	this	DET
bjp-38807	119	93	article	article	NOUN
bjp-38807	119	94	was	be	AUX
bjp-38807	119	95	downloaded	download	VERB
bjp-38807	119	96	by	by	ADP
bjp-38807	119	97	you	you	PRON
bjp-38807	119	98	on	on	ADP
bjp-38807	119	99	:	:	PUNCT
bjp-38807	119	100	feb	feb	PROPN
bjp-38807	119	101	09	09	NUM
bjp-38807	119	102	,	,	PUNCT
bjp-38807	119	103	2019	2019	NUM